1
|
April MD, Bridwell RE, Davis WT, Oliver JJ, Long B, Fisher AD, Ginde AA, Schauer SG. Interventions associated with survival after prehospital intubation in the deployed combat setting. Am J Emerg Med 2024; 79:79-84. [PMID: 38401229 DOI: 10.1016/j.ajem.2024.01.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Revised: 12/19/2023] [Accepted: 01/30/2024] [Indexed: 02/26/2024] Open
Abstract
INTRODUCTION Airway compromise is the second leading cause of potentially preventable death on the battlefield. Prehospital airway management is often unavoidable in a kinetic combat environment and expected to increase in future wars where timely evacuation will be unreliable and air superiority not guaranteed. We compared characteristics of survivors to non-survivors among combat casualties undergoing prehospital airway intubation. MATERIALS AND METHODS We requested all Department of Defense Trauma Registry (DODTR) encounters during 2007-2023 with documentation of any airway intervention or assessment within the first 72-h after injury. We conducted a retrospective cohort study of all casualties with intubation documented in the prehospital setting. We used descriptive and inferential statistical analysis to compare survivors through 7 days post injury versus non-survivors. We constructed 3 multivariable logistic regression models to test for associations between interventions and 7-day survival after adjusting for injury severity score, mechanism of injury, and receipt of sedatives, paralytics, and blood products. RESULTS There were 1377 of 48,301 patients with documentation of prehospital intubation in a combat setting. Of these, 1028 (75%) survived through 7 days post injury. Higher proportions of survivors received ketamine, paralytic agents, parenteral opioids, and parenteral benzodiazepines; there was no difference in the proportions of survivors versus non-survivors receiving etomidate. The multivariable models consistently demonstrated positive associations between 7-day survival and receipt of non-depolarizing paralytics and opioid analgesics. CONCLUSIONS We found an association between non-depolarizing paralytic and opioid receipt with 7-day survival among patients undergoing prehospital intubation. The literature would benefit from future multi-center randomized controlled trials to establish optimal pharmacologic strategies for trauma patients undergoing prehospital intubation.
Collapse
Affiliation(s)
- Michael D April
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA; 14th Field Hospital, Fort Stewart, GA, USA.
| | - Rachel E Bridwell
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, WA, USA
| | - William T Davis
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Joshua J Oliver
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, WA, USA
| | - Brit Long
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Andrew D Fisher
- Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM, USA
| | - Adit A Ginde
- Departments of Emergency Medicine and Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA; Center for Combat and Battlefield (COMBAT) Research, University of Colorado School of Medicine, Aurora, CO, USA
| | - Steven G Schauer
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Departments of Emergency Medicine and Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA; Center for Combat and Battlefield (COMBAT) Research, University of Colorado School of Medicine, Aurora, CO, USA
| |
Collapse
|
2
|
Lewis NM, Zhu Y, Peltan ID, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Duggal A, Bender WS, Taghizadeh L, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Wilson JG, Qadir N, Chang SY, Ginde AA, Mohr NM, Mallow C, Lauring AS, Johnson NJ, Gibbs KW, Kwon JH, Columbus C, Gottlieb RL, Raver C, Vaughn IA, Ramesh M, Johnson C, Lamerato L, Safdar B, Casey JD, Rice TW, Halasa N, Chappell JD, Grijalva CG, Talbot HK, Baughman A, Womack KN, Swan SA, Harker E, Price A, DeCuir J, Surie D, Ellington S, Self WH. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis 2024; 78:1056-1064. [PMID: 38051664 DOI: 10.1093/cid/ciad677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Accepted: 11/07/2023] [Indexed: 12/07/2023] Open
Abstract
BACKGROUND Influenza circulation during the 2022-2023 season in the United States largely returned to pre-coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. Influenza A(H3N2) viruses were detected most frequently this season, predominately clade 3C.2a1b.2a, a close antigenic match to the vaccine strain. METHODS To understand effectiveness of the 2022-2023 influenza vaccine against influenza-associated hospitalization, organ failure, and death, a multicenter sentinel surveillance network in the United States prospectively enrolled adults hospitalized with acute respiratory illness between 1 October 2022, and 28 February 2023. Using the test-negative design, vaccine effectiveness (VE) estimates against influenza-associated hospitalization, organ failures, and death were measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2-negative control-patients. RESULTS A total of 3707 patients, including 714 influenza cases (33% vaccinated) and 2993 influenza- and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative controls (49% vaccinated) were analyzed. VE against influenza-associated hospitalization was 37% (95% confidence interval [CI]: 27%-46%) and varied by age (18-64 years: 47% [30%-60%]; ≥65 years: 28% [10%-43%]), and virus (A[H3N2]: 29% [6%-46%], A[H1N1]: 47% [23%-64%]). VE against more severe influenza-associated outcomes included: 41% (29%-50%) against influenza with hypoxemia treated with supplemental oxygen; 65% (56%-72%) against influenza with respiratory, cardiovascular, or renal failure treated with organ support; and 66% (40%-81%) against influenza with respiratory failure treated with invasive mechanical ventilation. CONCLUSIONS During an early 2022-2023 influenza season with a well-matched influenza vaccine, vaccination was associated with reduced risk of influenza-associated hospitalization and organ failure.
Collapse
Affiliation(s)
- Nathaniel M Lewis
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Yuwei Zhu
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Ithan D Peltan
- Department of Medicine, Intermountain Medical Center, Murray, Utah, and University of Utah, Salt Lake City, Utah, USA
| | - Manjusha Gaglani
- Baylor Scott and White Health, Temple and Dallas, Texas, and Texas A&M University College of Medicine, Temple, Texas, USA
| | - Tresa McNeal
- Baylor Scott and White Health, and Baylor College of Medicine, Temple, Texas, USA
| | - Shekhar Ghamande
- Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Jay S Steingrub
- Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA
| | - Nathan I Shapiro
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Abhijit Duggal
- Department of Medicine, Cleveland Clinic, Cleveland, Ohio, USA
| | | | - Leyla Taghizadeh
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
| | - Samuel M Brown
- Department of Medicine, Intermountain Medical Center, Murray, Utah, and University of Utah, Salt Lake City, Utah, USA
| | - David N Hager
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Michelle N Gong
- Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Amira Mohamed
- Department of Medicine, The Ohio State University, Columbus, Ohio, USA
| | - Matthew C Exline
- Department of Medicine, The Ohio State University, Columbus, Ohio, USA
| | - Akram Khan
- Department of Medicine, Oregon Health and Sciences University, Portland, Oregon, USA
| | - Jennifer G Wilson
- Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Nida Qadir
- Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA
| | - Steven Y Chang
- Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Nicholas M Mohr
- Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
| | | | - Adam S Lauring
- Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
| | - Nicholas J Johnson
- Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA
| | - Kevin W Gibbs
- Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Jennie H Kwon
- Department of Medicine, Washington University, St.Louis, Missouri, USA
| | | | - Robert L Gottlieb
- Baylor University Medical Center Dallas, Baylor, Scott & White Heart and Vascular Hospital, Baylor, Scott and White Research Institute, Dallas, Texas, USA
| | | | - Ivana A Vaughn
- Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA
| | - Mayur Ramesh
- Division of Infectious Diseases, Henry Ford Health, Detroit, Michigan, USA
| | - Cassandra Johnson
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Lois Lamerato
- Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA
| | - Basmah Safdar
- Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Jonathan D Casey
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Todd W Rice
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Natasha Halasa
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Carlos G Grijalva
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - H Keipp Talbot
- Departments of Medicine and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adrienne Baughman
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kelsey N Womack
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Sydney A Swan
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Elizabeth Harker
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Ashley Price
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Jennifer DeCuir
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Diya Surie
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Sascha Ellington
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt Institute for Clinical and Translational Research, and Vanderbilt University Medical Center, Nashville, Tennessee, USA
| |
Collapse
|
3
|
Levin MJ, Ginde AA, Schmid DS, Lang N, Canniff J, Schwartz RS, Weinberg A. Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents. Vaccine 2024; 42:2278-2281. [PMID: 38423817 DOI: 10.1016/j.vaccine.2024.02.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 02/07/2024] [Accepted: 02/17/2024] [Indexed: 03/02/2024]
Abstract
Thirty-three long-term care residents (mean age 76.5 years), who were participating in a study in which they were randomized to receive either oral daily standard dose (400-1000 IU/day) 25-hydroxy vitamin D (vitamin D3) (SD) or high dose (3000-4000 IU/day) (HD) vitamin D3, were vaccinated with the live, attenuated herpes zoster vaccine. Blood was drawn at vaccination and three weeks later to determine varicella-zoster virus (VZV) antibody and T-cell mediated immune responses. ELISA and neutralizing antibodies increased significantly, but to the same extent, in both groups. The antibody avidity significantly increased from pre- to post-vaccination only in the HD group. VZV-CMI, as measured by FLUOROSPOT significantly increased post-vaccination in both groups, but the difference in interferon-γ spot-forming cells (SFC) and interleukin-2 SFC was lower in the HD than SD group. The increase in VZV-CMI correlated inversely with circulating regulatory T cells in the HD group. We conclude that pre-treatment with HD vitamin D3 does not appreciably enhance the antibody response to a live vaccine and that VZV-CMI responses were diminished in HD vitamin D3 recipients.
Collapse
Affiliation(s)
- Myron J Levin
- Departments of Pediatrics and Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States
| | - D Scott Schmid
- University of Colorado, Boulder, CO, United States; Previously Viral Vaccine Preventable Diseases Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Nancy Lang
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States
| | - Jennifer Canniff
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States
| | - Robert S Schwartz
- Division of Geriatric Medicine, University of Colorado School of Medicine, Aurora, CO, United States; Eastern Colorado VA Geriatric Research, Education and Clinical Center, Denver, CO, United States
| | - Adriana Weinberg
- Departments of Pediatrics, Medicine, and Pathology, University of Colorado School of Medicine, Aurora, CO, United States
| |
Collapse
|
4
|
Surie D, Yuengling KA, DeCuir J, Zhu Y, Lauring AS, Gaglani M, Ghamande S, Peltan ID, Brown SM, Ginde AA, Martinez A, Mohr NM, Gibbs KW, Hager DN, Ali H, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Leis AM, Khan A, Hough CL, Bender WS, Duggal A, Bendall EE, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Exline MC, Shapiro NI, Columbus C, Vaughn IA, Ramesh M, Mosier JM, Safdar B, Casey JD, Talbot HK, Rice TW, Halasa N, Chappell JD, Grijalva CG, Baughman A, Womack KN, Swan SA, Johnson CA, Lwin CT, Lewis NM, Ellington S, McMorrow ML, Martin ET, Self WH. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open 2024; 7:e244954. [PMID: 38573635 DOI: 10.1001/jamanetworkopen.2024.4954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/05/2024] Open
Abstract
Importance On June 21, 2023, the Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccines for adults aged 60 years and older using shared clinical decision-making. Understanding the severity of RSV disease in adults can help guide this clinical decision-making. Objective To describe disease severity among adults hospitalized with RSV and compare it with the severity of COVID-19 and influenza disease by vaccination status. Design, Setting, and Participants In this cohort study, adults aged 18 years and older admitted to the hospital with acute respiratory illness and laboratory-confirmed RSV, SARS-CoV-2, or influenza infection were prospectively enrolled from 25 hospitals in 20 US states from February 1, 2022, to May 31, 2023. Clinical data during each patient's hospitalization were collected using standardized forms. Data were analyzed from August to October 2023. Exposures RSV, SARS-CoV-2, or influenza infection. Main Outcomes and Measures Using multivariable logistic regression, severity of RSV disease was compared with COVID-19 and influenza severity, by COVID-19 and influenza vaccination status, for a range of clinical outcomes, including the composite of invasive mechanical ventilation (IMV) and in-hospital death. Results Of 7998 adults (median [IQR] age, 67 [54-78] years; 4047 [50.6%] female) included, 484 (6.1%) were hospitalized with RSV, 6422 (80.3%) were hospitalized with COVID-19, and 1092 (13.7%) were hospitalized with influenza. Among patients with RSV, 58 (12.0%) experienced IMV or death, compared with 201 of 1422 unvaccinated patients with COVID-19 (14.1%) and 458 of 5000 vaccinated patients with COVID-19 (9.2%), as well as 72 of 699 unvaccinated patients with influenza (10.3%) and 20 of 393 vaccinated patients with influenza (5.1%). In adjusted analyses, the odds of IMV or in-hospital death were not significantly different among patients hospitalized with RSV and unvaccinated patients hospitalized with COVID-19 (adjusted odds ratio [aOR], 0.82; 95% CI, 0.59-1.13; P = .22) or influenza (aOR, 1.20; 95% CI, 0.82-1.76; P = .35); however, the odds of IMV or death were significantly higher among patients hospitalized with RSV compared with vaccinated patients hospitalized with COVID-19 (aOR, 1.38; 95% CI, 1.02-1.86; P = .03) or influenza disease (aOR, 2.81; 95% CI, 1.62-4.86; P < .001). Conclusions and Relevance Among adults hospitalized in this US cohort during the 16 months before the first RSV vaccine recommendations, RSV disease was less common but similar in severity compared with COVID-19 or influenza disease among unvaccinated patients and more severe than COVID-19 or influenza disease among vaccinated patients for the most serious outcomes of IMV or death.
Collapse
Affiliation(s)
- Diya Surie
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Katharine A Yuengling
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Jennifer DeCuir
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Yuwei Zhu
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Adam S Lauring
- Department of Internal Medicine, University of Michigan, Ann Arbor
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor
| | - Manjusha Gaglani
- Baylor Scott & White Health, Temple, Texas
- Texas A&M University College of Medicine, Temple
- Baylor College of Medicine, Temple, Texas
| | - Shekhar Ghamande
- Baylor Scott & White Health, Temple, Texas
- Texas A&M University College of Medicine, Temple
- Baylor College of Medicine, Temple, Texas
| | - Ithan D Peltan
- Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City
| | - Samuel M Brown
- Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora
| | - Amanda Martinez
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora
| | | | - Kevin W Gibbs
- Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - David N Hager
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Harith Ali
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Matthew E Prekker
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota
| | - Michelle N Gong
- Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
| | - Amira Mohamed
- Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
| | - Nicholas J Johnson
- Department of Emergency Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle
| | | | - Jay S Steingrub
- Department of Medicine, Baystate Medical Center, Springfield, Massachusetts
| | - Aleda M Leis
- School of Public Health, University of Michigan, Ann Arbor
| | - Akram Khan
- Department of Medicine, Oregon Health and Sciences University, Portland
| | - Catherine L Hough
- Department of Medicine, Oregon Health and Sciences University, Portland
| | | | - Abhijit Duggal
- Department of Medicine, Cleveland Clinic, Cleveland, Ohio
| | - Emily E Bendall
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor
| | - Jennifer G Wilson
- Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California
| | - Nida Qadir
- Department of Medicine, University of California, Los Angeles
| | - Steven Y Chang
- Department of Medicine, University of California, Los Angeles
| | | | - Jennie H Kwon
- Department of Medicine, Washington University in St Louis, St Louis, Missouri
| | | | - Nathan I Shapiro
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - Cristie Columbus
- Baylor Scott &White Health, Dallas, Texas
- Texas A&M University College of Medicine, Dallas
| | - Ivana A Vaughn
- Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan
| | - Mayur Ramesh
- Division of Infectious Diseases, Henry Ford Health, Detroit, Michigan
| | - Jarrod M Mosier
- Department of Emergency Medicine, University of Arizona, Tucson
| | - Basmah Safdar
- Yale University School of Medicine, New Haven, Connecticut
| | - Jonathan D Casey
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - H Keipp Talbot
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Todd W Rice
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Natasha Halasa
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Carlos G Grijalva
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Adrienne Baughman
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Kelsey N Womack
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Sydney A Swan
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Cassandra A Johnson
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Cara T Lwin
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Nathaniel M Lewis
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Sascha Ellington
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Meredith L McMorrow
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Emily T Martin
- School of Public Health, University of Michigan, Ann Arbor
| | - Wesley H Self
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee
| |
Collapse
|
5
|
Roberts SC, Jolley SE, Beaty LE, Aggarwal NR, Bennett TD, Carlson NE, Fish LE, Kwan BM, Russell S, Wogu AF, Wynia MA, Ginde AA. Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19. J Med Virol 2024; 96:e29541. [PMID: 38516779 PMCID: PMC10963040 DOI: 10.1002/jmv.29541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/20/2024] [Accepted: 03/06/2024] [Indexed: 03/23/2024]
Abstract
Effective therapies for reducing post-acute sequelae of COVID-19 (PASC) symptoms are lacking. Evaluate the association between monoclonal antibody (mAb) treatment or COVID-19 vaccination with symptom recovery in COVID-19 participants. The longitudinal survey-based cohort study was conducted from April 2021 to January 2022 across a multihospital Colorado health system. Adults ≥18 years with a positive SARS-CoV-2 test were included. Primary exposures were mAb treatment and COVID-19 vaccination. The primary outcome was time to symptom resolution after SARS-CoV-2 positive test date. The secondary outcome was hospitalization within 28 days of a positive SARS-CoV-2 test. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. COVID-19 vaccination, but not mAb therapy, was associated with a shorter time to symptom resolution. Both were associated with lower 28-day hospitalization.
Collapse
Affiliation(s)
- Samantha C Roberts
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA
| | - Sarah E Jolley
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Laurel E Beaty
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA
| | - Neil R Aggarwal
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Tellen D Bennett
- Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA
- Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Nichole E Carlson
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA
- Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Lindsey E Fish
- Division of General Internal Medicine, Denver Health and Hospital, Denver, Colorado, USA
| | - Bethany M Kwan
- Department of Family Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Seth Russell
- Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Adane F Wogu
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA
| | - Matthew A Wynia
- Department of Medicine, Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
- Center for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| |
Collapse
|
6
|
Aggarwal NR, Beaty LE, Bennett TD, Fish LE, Jacobs JR, Mayer DA, Molina KC, Peers JL, Richardson DB, Russell S, Varela A, Webb BJ, Wynia MK, Xiao M, Carlson NE, Ginde AA. Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study. Lancet Reg Health Am 2024; 31:100693. [PMID: 38500962 PMCID: PMC10945426 DOI: 10.1016/j.lana.2024.100693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 11/15/2023] [Accepted: 01/26/2024] [Indexed: 03/20/2024]
Abstract
Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 among high-risk individuals infected with earlier variants, but less is known about its effectiveness against omicron variants BQ.1/BQ.1.1/XBB.1.5. We sought to evaluate effectiveness of NMV-r in BQ.1/BQ.1.1/XBB.1.5 omicron variants by comparing hospitalisation rates to NMV-r treated patients during a previous omicron phase and to contemporaneous untreated patients. Methods We conducted a retrospective observational cohort study of non-hospitalised adult patients with SARS-CoV-2 infection using real-world data from three health systems in Colorado and Utah, and compared hospitalisation rates in NMV-r-treated patients in a BA.2/BA.2.12.1/BA.4/BA.5 variant-predominant (first) phase (April 3, 2022-November 12, 2022), with a BQ.1/BQ.1.1/XBB.1.5 variant-predominant (second) phase (November 13, 2022-March 7, 2023). In the primary analysis, we used Firth logistic regression with a two-segment (phase) linear time model, and pre-specified non-inferiority bounds for the mean change between segments. In a pre-specified secondary analysis, we inferred NMV-r effectiveness in a cohort of treated and untreated patients infected during the second phase. For both analyses, the primary outcome was 28-day all-cause hospitalisation. Subgroup analyses assessed treatment effect heterogeneity. Findings In the primary analysis, 28-day all-cause hospitalisation rates in NMV-r treated patients in the second phase (n = 12,061) were non-inferior compared to the first phase (n = 25,075) (198 [1.6%] vs. 345 [1.4%], adjusted odds ratio (aOR): 0.76 [95% CI 0.54-1.06]), with consistent results among secondary endpoints and key subgroups. Secondary cohort analyses revealed additional evidence for NMV-r effectiveness, with reduced 28-day hospitalisation rates among treated patients compared to untreated patients during a BQ.1/BQ.1.1/XBB.1.5 predominant phase (198/12,061 [1.6%] vs. 376/10,031 [3.7%], aOR 0.34 [95% CI 0.30-0.38), findings robust to additional sensitivity analyses. Interpretation Real-world evidence from major US healthcare systems suggests ongoing NMV-r effectiveness in preventing hospitalisation during a BQ.1/BQ.1.1/XBB.1.5-predominant phase in the U.S, supporting its continued use in similar patient populations. Funding U.S. National Institutes of Health.
Collapse
Affiliation(s)
- Neil R. Aggarwal
- Department of Medicine, Division of Pulmonary Sciences and Critical Care, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| | - Laurel E. Beaty
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Tellen D. Bennett
- Departments of Biomedical Informatics and Pediatrics, University of Colorado School of Medicine, Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
| | - Lindsey E. Fish
- Division of General Internal Medicine, Denver Health and Hospital and University of Colorado School of Medicine, Denver, CO, 80204, USA
| | - Jason R. Jacobs
- Pulmonology and Critical Care Medicine Research, Intermountain Health, Murray, UT, 84107, USA
| | - David A. Mayer
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Kyle C. Molina
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| | - Jennifer L. Peers
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| | - Douglas B. Richardson
- Division of General Internal Medicine, Denver Health and Hospital and University of Colorado School of Medicine, Denver, CO, 80204, USA
| | - Seth Russell
- Departments of Biomedical Informatics and Pediatrics, University of Colorado School of Medicine, Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
| | - Alejandro Varela
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Brandon J. Webb
- Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, 84107, USA
| | - Matthew K. Wynia
- Department of Medicine, Division of Pulmonary Sciences and Critical Care, University of Colorado School of Medicine, Aurora, CO, 80045, USA
- Department of Health Systems Management and Policy, University of Colorado Center for Bioethics and Humanities, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
| | - Mengli Xiao
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Nichole E. Carlson
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Adit A. Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| |
Collapse
|
7
|
Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, Martin ET, House S, Saade EA, Zimmerman RK, Gaglani M, Wernli KJ, Walter EB, Michaels MG, Staat MA, Weinberg GA, Selvarangan R, Boom JA, Klein EJ, Halasa NB, Ginde AA, Gibbs KW, Zhu Y, Self WH, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Weber ZA, Yang DH, Ball SW, Surie D, DeCuir J, Dawood FS, Moline HL, Toepfer AP, Clopper BR, Link-Gelles R, Payne AB, Chung JR, Flannery B, Lewis NM, Olson SM, Adams K, Tenforde MW, Garg S, Grohskopf LA, Reed C, Ellington S. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. MMWR Morb Mortal Wkly Rep 2024; 73:168-174. [PMID: 38421935 PMCID: PMC10907036 DOI: 10.15585/mmwr.mm7308a3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/02/2024]
Abstract
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged ≥6 months with acute respiratory illness-associated medical encounters using a test-negative case-control study design. Among children and adolescents aged 6 months-17 years, VE against influenza-associated outpatient visits ranged from 59% to 67% and against influenza-associated hospitalization ranged from 52% to 61%. Among adults aged ≥18 years, VE against influenza-associated outpatient visits ranged from 33% to 49% and against hospitalization from 41% to 44%. VE against influenza A ranged from 46% to 59% for children and adolescents and from 27% to 46% for adults across settings. VE against influenza B ranged from 64% to 89% for pediatric patients in outpatient settings and from 60% to 78% for all adults across settings. These findings demonstrate that the 2023-24 seasonal influenza vaccine is effective at reducing the risk for medically attended influenza virus infection. CDC recommends that all persons aged ≥6 months who have not yet been vaccinated this season get vaccinated while influenza circulates locally.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - CDC Influenza Vaccine Effectiveness Collaborators
- Influenza Division, National Center for Immunization and Respiratory Diseases, CDC; Epidemic Intelligence Service, CDC; Biodesign Center for Personalized Diagnostics, Arizona State University, Tempe, Arizona; University of Michigan School of Public Health, Ann Arbor, Michigan; Washington University School of Medicine in St. Louis, St. Louis, Missouri; University Hospitals of Cleveland, Cleveland, Ohio; University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Baylor Scott & White Health, Temple, Texas; Baylor College of Medicine, Temple, Texas; Texas A&M University College of Medicine, Temple, Texas; Kaiser Permanente Washington Health Research Institute, Seattle, Washington; Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina; UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania; University of Cincinnati College of Medicine, Cincinnati, Ohio; Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; University of Rochester School of Medicine and Dentistry, Rochester, New York; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri; Children’s Mercy Hospital, Kansas City, Missouri; Baylor College of Medicine, Houston, Texas; Texas Children’s Hospital, Houston, Texas; Seattle Children’s Research Institute, Seattle, Washington; Vanderbilt University Medical Center, Nashville, Tennessee; University of Colorado School of Medicine, Aurora, Colorado; Wake Forest University School of Medicine, Winston-Salem, North Carolina; Kaiser Permanente Department of Research & Evaluation, Pasadena, California; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah; HealthPartners Institute, Minneapolis, Minnesota; Westat, Rockville, Maryland; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC
| |
Collapse
|
8
|
DeCuir J, Payne AB, Self WH, Rowley EA, Dascomb K, DeSilva MB, Irving SA, Grannis SJ, Ong TC, Klein NP, Weber ZA, Reese SE, Ball SW, Barron MA, Naleway AL, Dixon BE, Essien I, Bride D, Natarajan K, Fireman B, Shah AB, Okwuazi E, Wiegand R, Zhu Y, Lauring AS, Martin ET, Gaglani M, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker M, Mohamed A, Srinivasan V, Steingrub JS, Khan A, Busse LW, Duggal A, Wilson JG, Chang SY, Mallow C, Kwon JH, Exline MC, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Casey JD, Chappell JD, Grijalva CG, Swan SA, Johnson C, Lewis NM, Ellington S, Adams K, Tenforde MW, Paden CR, Dawood FS, Fleming-Dutra KE, Surie D, Link-Gelles R. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep 2024; 73:180-188. [PMID: 38421945 PMCID: PMC10907041 DOI: 10.15585/mmwr.mm7308a5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/02/2024]
Abstract
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19-associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023-January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19-associated ED/UC encounters was 51% (95% CI = 47%-54%) during the first 7-59 days after an updated dose and 39% (95% CI = 33%-45%) during the 60-119 days after an updated dose. VE estimates against COVID-19-associated hospitalization from two CDC VE networks were 52% (95% CI = 47%-57%) and 43% (95% CI = 27%-56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19-associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023-2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccine.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - CDC COVID-19 Vaccine Effectiveness Collaborators
- Coronavirus and Other
Respiratory Viruses Division, National Center for Immunization and Respiratory
Diseases, CDC; Vanderbilt University Medical Center, Nashville,
Tennessee; Westat,
Rockville, Maryland; Division of Infectious Diseases and Clinical Epidemiology,
Intermountain Healthcare, Salt Lake City, Utah; HealthPartners Institute,
Minneapolis, Minnesota; Kaiser Permanente Center for Health Research,
Portland, Oregon; Indiana University School of Medicine, Indianapolis,
Indiana; Regenstrief
Institute Center for Biomedical Informatics, Indianapolis, Indiana; University of Colorado
School of Medicine, Aurora, Colorado; Kaiser Permanente Vaccine Study Center, Kaiser
Permanente Northern California Division of Research, Oakland, California;
Department of
Biomedical Informatics, Columbia University Irving Medical Center, New York, New
York; New
York-Presbyterian Hospital, New York, New York; General Dynamics Information
Technology, Falls Church, Virginia; University of Michigan, Ann Arbor, Michigan;
Baylor Scott
& White Health, Texas; Baylor College of Medicine, Temple, Texas; Intermountain Medical
Center, Murray, Utah; University of Utah, Salt Lake City, Utah; University of Iowa, Iowa
City, Iowa; Wake
Forest School of Medicine, Winston-Salem, North Carolina; Johns Hopkins University School of
Medicine, Baltimore, Maryland; Hennepin County Medical Center, Minneapolis,
Minnesota; Montefiore
Medical Center, Albert Einstein College of Medicine, New York, New York; University of Washington,
Seattle, Washington; Baystate Medical Center, Springfield, Massachusetts;
Oregon Health
& Science University, Portland, Oregon; Emory University, Atlanta, Georgia; Cleveland Clinic,
Cleveland, Ohio; Stanford University School of Medicine, Stanford,
California; Ronald
Reagan UCLA Medical Center, Los Angeles, California; University of Miami, Miami, Florida;
Washington
University in St. Louis, St. Louis, Missouri; The Ohio State University, Columbus,
Ohio; Texas A&M
University College of Medicine, Dallas, Texas; Henry Ford Health, Detroit,
Michigan; Yale
University School of Medicine, New Haven, Connecticut; University of Arizona, Tucson,
Arizona; Influenza
Division, National Center for Immunization and Respiratory Diseases, CDC
| |
Collapse
|
9
|
Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clin Infect Dis 2024:ciad780. [PMID: 38376212 DOI: 10.1093/cid/ciad780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Indexed: 02/21/2024] Open
Abstract
BACKGROUND Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was to evaluate which virus and host response factors were associated with mortality risk among participants in Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) trials. METHODS A secondary analysis of 2625 adults hospitalized for acute SARS-CoV-2 infection randomized to 1 of 5 antiviral products or matched placebo in 114 centers on 4 continents. Uniform, site-level collection of participant baseline clinical variables was performed. Research laboratories assayed baseline upper respiratory swabs for SARS-CoV-2 viral RNA and plasma for anti-SARS-CoV-2 antibodies, SARS-CoV-2 nucleocapsid antigen (viral Ag), and interleukin-6 (IL-6). Associations between factors and time to mortality by 90 days were assessed using univariate and multivariable Cox proportional hazards models. RESULTS Viral Ag ≥4500 ng/L (vs <200 ng/L; adjusted hazard ratio [aHR], 2.07; 1.29-3.34), viral RNA (<35 000 copies/mL [aHR, 2.42; 1.09-5.34], ≥35 000 copies/mL [aHR, 2.84; 1.29-6.28], vs below detection), respiratory support (<4 L O2 [aHR, 1.84; 1.06-3.22]; ≥4 L O2 [aHR, 4.41; 2.63-7.39], or noninvasive ventilation/high-flow nasal cannula [aHR, 11.30; 6.46-19.75] vs no oxygen), renal impairment (aHR, 1.77; 1.29-2.42), and IL-6 >5.8 ng/L (aHR, 2.54 [1.74-3.70] vs ≤5.8 ng/L) were significantly associated with mortality risk in final adjusted analyses. Viral Ag, viral RNA, and IL-6 were not measured in real-time. CONCLUSIONS Baseline virus-specific, clinical, and biological variables are strongly associated with mortality risk within 90 days, revealing potential pathogen and host-response therapeutic targets for acute COVID-19 disease.
Collapse
Affiliation(s)
- Neil R Aggarwal
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Jacquie Nordwall
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - Dominique L Braun
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Lucy Chung
- CAMRIS International (under contract no. 75N93019D00025 with National Institute of Allergy and Infectious Diseases, Department of Health and Human Services), National Institute of Health, Bethesda, Maryland, USA
| | - Jordan Coslet
- Velocity Clinical Research, Chula Vista, California, USA
| | - Tatyana Der
- Department of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina, USA
| | | | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Awori J Hayanga
- Department of Cardiovascular Thoracic Surgery, West Virginia University School of Medicine, Morgantown, West Virginia, USA
| | - Helene Highbarger
- Virus Isolation and Serology Laboratory, Frederick National Laboratory, National Cancer Institute, Frederick, Maryland, USA
| | - Mark Holodniy
- Veterans Affairs Palo Alto Health Care System, Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, California, USA
| | - Juan P Horcajada
- Department of Infectious Diseases, Hospital del Mar Research Insititute, UPF, Barcelona, Spain
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain
| | - Mamta K Jain
- Division of Infectious Diseases and Geotropical Medicine, UT Southwestern Medical Center and Parkland Health and Hospital System, Dallas, Texas, USA
| | - Kami Kim
- Division of Infectious Disease and International Medicine, Morsani College of Medicine, University of South Florida and Global Emerging Diseases Institute, Tampa General Hospital, Tampa, Florida, USA
| | - Sylvain Laverdure
- Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory, National Cancer Institute, Frederick, Maryland, USA
| | - Jens Lundgren
- CHIP Center of Excellence for Health, Immunity, and Infections and Department of Infectious Diseases, Righospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Ven Natarajan
- Laboratory of Molecular Cell Biology, Frederick National Laboratory, National Cancer Institute, Frederick, Maryland, USA
| | - Hien H Nguyen
- Division of Infectious Diseases, Veterans Affairs Northern California, University of California, Davis, Sacramento, California, USA
| | - Sarah L Pett
- The Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom
- Institute for Global Health, University College London, London, United Kingdom
| | - Andrew Phillips
- Institute for Global Health, University College London, London, United Kingdom
| | - Garyphallia Poulakou
- Third Department of Medicine and Laboratory National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - David A Price
- Newcastle Upon Tyne NHUS Hospitals Foundation Trust, Newcastle Upon Tyne, United Kingdom
| | - Philip Robinson
- Infection Prevention and Hospital Epidemiology, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
| | - Angela J Rogers
- Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University, Palo Alto, California, USA
| | - Uriel Sandkovsky
- Division of Infectious Diseases, Baylor University Medical Center, Dallas, Texas, USA
| | - Katy Shaw-Saliba
- National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, Maryland, USA
| | - Jeffrey M Sturek
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, UVA Health, Charlottesville, Virginia, USA
| | - Barbara W Trautner
- Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA
| | - Michael Waters
- Velocity Clinical Research, Chula Vista, California, USA
| | - Cavan Reilly
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| |
Collapse
|
10
|
Wendel SK, Wogu AF, Carlson NE, Beaty L, Bennett TD, Bookman K, Mayer DA, Michael SM, Molina KC, Peers JL, Russell S, Zane RD, Ginde AA. Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID-19. J Am Coll Emerg Physicians Open 2024; 5:e13116. [PMID: 38384380 PMCID: PMC10879902 DOI: 10.1002/emp2.13116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 12/28/2023] [Accepted: 01/19/2024] [Indexed: 02/23/2024] Open
Abstract
Objectives To evaluate whether subcutaneous neutralizing monoclonal antibody (mAb) treatment given in the emergency department (ED) setting was associated with reduced hospitalizations, mortality, and severity of disease when compared to nontreatment among mAb-eligible patients with coronavirus disease 2019 (COVID-19). Methods This retrospective observational cohort study of ED patients utilized a propensity score-matched analysis to compare patients who received subcutaneous casirivimab and imdevimab mAb to nontreated COVID-19 control patients in November-December 2021. The primary outcome was all-cause hospitalization within 28 days, and secondary outcomes were 90-day hospitalization, 28- and 90-day mortality, and ED length of stay (LOS). Results Of 1340 patients included in the analysis, 490 received subcutaneous casirivimab and imdevimab, and 850 did not received them. There was no difference observed for 28-day hospitalization (8.4% vs. 10.6%; adjusted odds ratio [aOR] 0.79, 95% confidence intervals [CI] 0.53-1.17) or 90-day hospitalization (11.6% vs. 12.5%; aOR 0.93, 95% CI 0.65-1.31). However, mortality at both the 28-day and 90-day timepoints was substantially lower in the treated group (28-day 0.6% vs. 3.1%; aOR 0.18, 95% CI 0.08-0.41; 90-day 0.6% vs. 3.9%; aOR 0.14, 95% CI 0.06-0.36). Among hospitalized patients, treated patients had shorter hospital LOS (5.7 vs. 11.4 days; adjusted rate ratio [aRR] 0.47, 95% CI 0.33-0.69), shorter intensive care unit LOS (3.8 vs. 10.2 days; aRR 0.22, 95% CI 0.14-0.35), and the severity of hospitalization was lower (aOR 0.45, 95% CI 0.21-0.97) compared to untreated. Conclusions Among ED patients who presented for symptomatic COVID-19 during the Delta variant phase, ED subcutaneous casirivimab/imdevimab treatment was not associated with a decrease in hospitalizations. However, treatment was associated with lower mortality at 28 and 90 days, hospital LOS, and overall severity of illness.
Collapse
Affiliation(s)
- Sarah K. Wendel
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
- Department of Emergency MedicineUniversity of Virginia School of MedicineCharlottesvilleVirginiaUSA
| | - Adane F. Wogu
- Department of Biostatistics and InformaticsColorado School of Public HealthAuroraColoradoUSA
| | - Nichole E. Carlson
- Department of Biostatistics and InformaticsColorado School of Public HealthAuroraColoradoUSA
| | - Laurel Beaty
- Department of Biostatistics and InformaticsColorado School of Public HealthAuroraColoradoUSA
| | - Tellen D. Bennett
- Departments of Biomedical Informatics and PediatricsUniversity of Colorado School of MedicineAuroraColoradoUSA
| | - Kelly Bookman
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
| | - David A. Mayer
- Department of Biostatistics and InformaticsColorado School of Public HealthAuroraColoradoUSA
| | - Sean M. Michael
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
| | - Kyle C. Molina
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
| | - Jennifer L. Peers
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
| | - Seth Russell
- Departments of Biomedical Informatics and PediatricsUniversity of Colorado School of MedicineAuroraColoradoUSA
- Colorado Clinical and Translational Sciences InstituteUniversity of Colorado Anschutz Medical CampusAuroraColoradoUSA
| | - Richard D. Zane
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
| | - Adit A. Ginde
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
| |
Collapse
|
11
|
Schauer SG, Long B, Fisher AD, Stednick PJ, Bebarta VS, Ginde AA, April MD. Time for the Department of Defense to Field Video Laryngoscopy Across the Battlespace. J Spec Oper Med 2023; 23:110-111. [PMID: 38029417 DOI: 10.55460/lz5v-qdh4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/01/2023] [Indexed: 12/01/2023]
|
12
|
Stewart TG, Rebolledo PA, Mourad A, Lindsell CJ, Boulware DR, McCarthy MW, Thicklin F, Garcia del Sol IT, Bramante CT, Lenert LA, Lim S, Williamson JC, Cardona OQ, Scott J, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Rothman RL, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S. Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA 2023; 330:2354-2363. [PMID: 37976072 PMCID: PMC10656670 DOI: 10.1001/jama.2023.23363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 10/25/2023] [Indexed: 11/19/2023]
Abstract
Importance The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. Objective To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treating mild to moderate COVID-19. Design, Setting, and Participants The ACTIV-6 platform randomized clinical trial aims to evaluate repurposed medications for mild to moderate COVID-19. Between August 25, 2022, and January 20, 2023, a total of 1175 participants were enrolled at 103 US sites for evaluating fluvoxamine; participants were 30 years or older with confirmed SARS-CoV-2 infection and at least 2 acute COVID-19 symptoms for 7 days or less. Interventions Participants were randomized to receive fluvoxamine, 50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days (n = 601), or placebo (n = 607). Main Outcomes and Measures The primary outcome was time to sustained recovery (defined as at least 3 consecutive days without symptoms). Secondary outcomes included time to death; time to hospitalization or death; a composite of hospitalization, urgent care visit, emergency department visit, or death; COVID-19 clinical progression scale score; and difference in mean time unwell. Follow-up occurred through day 28. Results Among 1208 participants who were randomized and received the study drug, the median (IQR) age was 50 (40-60) years, 65.8% were women, 45.5% identified as Hispanic/Latino, and 76.8% reported receiving at least 2 doses of a SARS-CoV-2 vaccine. Among 589 participants who received fluvoxamine and 586 who received placebo included in the primary analysis, differences in time to sustained recovery were not observed (adjusted hazard ratio [HR], 0.99 [95% credible interval, 0.89-1.09]; P for efficacy = .40]). Additionally, unadjusted median time to sustained recovery was 10 (95% CI, 10-11) days in both the intervention and placebo groups. No deaths were reported. Thirty-five participants reported health care use events (a priori defined as death, hospitalization, or emergency department/urgent care visit): 14 in the fluvoxamine group compared with 21 in the placebo group (HR, 0.69 [95% credible interval, 0.27-1.21]; P for efficacy = .86) There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) but no deaths. Conclusions and Relevance Among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of COVID-19 symptoms. Trial Registration ClinicalTrials.gov Identifier: NCT04885530.
Collapse
Affiliation(s)
| | - Paulina A. Rebolledo
- Department of Medicine and Global Health, Division of Infectious Diseases, Emory University School of Medicine and Rollins School of Public Health, Atlanta, Georgia
| | - Ahmad Mourad
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | | | - David R. Boulware
- University of Minnesota Medical School, General Internal Medicine, Minneapolis
| | | | | | | | - Carolyn T. Bramante
- University of Minnesota Medical School, General Internal Medicine, Minneapolis
| | | | - Stephen Lim
- Louisiana State University Health Sciences Center New Orleans, University Medical Center New Orleans, New Orleans
| | - John C. Williamson
- Wake Forest University School of Medicine, Department of Internal Medicine, Section on Infectious Diseases, Winston-Salem, North Carolina
| | - Orlando Quintero Cardona
- Stanford University School of Medicine, Department of Medicine, Infectious Diseases and Geographic Medicine Division, Stanford, California
| | - Jake Scott
- Stanford University School of Medicine, Department of Medicine, Infectious Diseases and Geographic Medicine Division, Stanford, California
| | | | | | - Mario Castro
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Missouri-Kansas City School of Medicine, Kansas City
| | - Dushyantha Jayaweera
- Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida
| | - Mark Sulkowski
- Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland
| | - Nina Gentile
- Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Kathleen McTigue
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - G. Michael Felker
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Allison DeLong
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Rhonda Wilder
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | | | - Sean Collins
- Vanderbilt University Medical Center, Nashville, Tennessee
- Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Nashville
| | - Sarah E. Dunsmore
- National Center for Advancing Translational Sciences, Bethesda, Maryland
| | - Stacey J. Adam
- Foundation for the National Institutes of Health, Bethesda, Maryland
| | - George J. Hanna
- Biomedical Advanced Research and Development Authority, Washington, DC
| | - Elizabeth Shenkman
- Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville
| | - Adrian F. Hernandez
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Susanna Naggie
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| |
Collapse
|
13
|
Young-Xu Y, Korves C, Zwain G, Satram S, Drysdale M, Reyes C, Cheng MM, Bonomo RA, Epstein L, Marconi VC, Ginde AA. Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During Omicron BA.1. Open Forum Infect Dis 2023; 10:ofad605. [PMID: 38152625 PMCID: PMC10751450 DOI: 10.1093/ofid/ofad605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 11/29/2023] [Indexed: 12/29/2023] Open
Abstract
Background The real-world clinical effectiveness of sotrovimab in preventing coronavirus disease 2019 (COVID-19)-related hospitalization or mortality among high-risk patients diagnosed with COVID-19, particularly after the emergence of the Omicron variant, needs further research. Method Using data from the US Department of Veterans Affairs (VA) health care system, we adopted a target trial emulation design in our study. Veterans aged ≥18 years, diagnosed with COVID-19 between December 1, 2021, and April 4, 2022, were included. Patients treated with sotrovimab (n = 2816) as part of routine clinical care were compared with all eligible but untreated patients (n = 11,250). Cox proportional hazards modeling estimated the hazard ratios (HRs) and 95% CIs for the association between receipt of sotrovimab and outcomes. Results Most (90%) sotrovimab recipients were ≥50 years old, and 64% had ≥2 mRNA vaccine doses or ≥1 dose of Ad26.COV2. During the period that BA.1 was dominant, compared with patients not treated, sotrovimab-treated patients had a 70% lower risk of hospitalization or mortality within 30 days (HR, 0.30; 95% CI, 0.23-0.40). During BA.2 dominance, sotrovimab-treated patients had a 71% (HR, 0.29; 95% CI, 0.08-0.98) lower risk of 30-day COVID-19-related hospitalization, emergency room visits, or urgent care visits (defined as severe COVID-19) compared with patients not treated. Conclusions Using national real-world data from high-risk and predominantly vaccinated veterans, administration of sotrovimab, compared with contemporary standard treatment regimens, was associated with reduced risk of 30-day COVID-19-related hospitalization or all-cause mortality during the Omicron BA.1 period.
Collapse
Affiliation(s)
- Yinong Young-Xu
- US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, Illinois, USA
- Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA
| | - Caroline Korves
- US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, Illinois, USA
- White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
| | - Gabrielle Zwain
- US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, Illinois, USA
- White River Junction Veterans Affairs Medical Center, White River Junction, Vermont
| | - Sacha Satram
- Vir Biotechnology, San Francisco, California, USA
| | | | | | | | - Robert A Bonomo
- US Department of Veterans Affairs, VA SHIELD, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA
- Case Western Reserve University, Cleveland, Ohio, USA
| | - Lauren Epstein
- Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Vincent C Marconi
- Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| |
Collapse
|
14
|
Hamer MK, Sobczak C, Whittington L, Bowyer RL, Koren R, Begay JA, Lum HD, Ginde AA, Wynia MK, Kwan BM. Real-world data to evaluate effects of a multi-level dissemination strategy on access, outcomes, and equity of monoclonal antibodies for COVID-19. J Clin Transl Sci 2023; 7:e258. [PMID: 38229899 PMCID: PMC10789982 DOI: 10.1017/cts.2023.679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 09/18/2023] [Accepted: 11/03/2023] [Indexed: 01/18/2024] Open
Abstract
Introduction Multi-level dissemination strategies are needed to increase equitable access to effective treatment for high-risk outpatients with COVID-19, particularly among patients from disproportionately affected communities. Yet assessing population-level impact of such strategies can be challenging. Methods In collaboration with key contributors in Colorado, we conducted a retrospective cohort study to evaluate a multi-level dissemination strategy for neutralizing monoclonal antibody (mAb) treatment. Real-world data included county-level, de-identified output from a statewide mAb referral registry linked with publicly available epidemiological data. Outcomes included weekly number of mAb referrals, unique referring clinicians, and COVID-19 hospitalization rates. We assessed weekly changes in outcomes after dissemination strategies launched in July 2021. Results Overall, mAb referrals increased from a weekly average of 3.0 to 15.5, with an increase of 1.3 to 42.1 additional referrals per county in each post-period week (p < .05). Number of referring clinicians increased from a weekly average of 2.2 to 9.7, with an additional 1.5 to 22.2 unique referring clinicians observed per county per week beginning 5 weeks post-launch (p < .001). Larger effects were observed in communities specifically prioritized by the dissemination strategies. There were no observed differences in COVID-19 hospitalization rates between counties with and without mAb treatment sites. Conclusion Real-world data can be used to estimate population impact of multi-level dissemination strategies. The launch of these strategies corresponded with increases in mAb referrals, but no apparent population-level effects on hospitalization outcomes. Strengths of this analytic approach include pragmatism and efficiency, whereas limitations include inability to control for other contemporaneous trends.
Collapse
Affiliation(s)
- Mika K. Hamer
- Center for Bioethics and Humanities, University of Colorado
Anschutz Medical Campus, Aurora, CO,
USA
| | - Chelsea Sobczak
- Department of Family Medicine, University of Colorado
Anschutz Medical Campus, Aurora, CO,
USA
| | | | | | - Ramona Koren
- Patient Partner/Community Affiliate, University of Colorado
Anschutz Medical Campus, Aurora, CO,
USA
| | - Joel A. Begay
- Johns Hopkins Center for Indigenous Health, Department of International
Health, Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD, USA
| | - Hillary D. Lum
- Division of Geriatric Medicine, Department of Medicine,
University of Colorado School of Medicine, Aurora,
CO, USA
| | - Adit A. Ginde
- Department of Emergency Medicine, University of Colorado
School of Medicine, Aurora, CO,
USA
- Colorado Clinical & Translational Sciences Institute,
University of Colorado Anschutz Medical Campus,
Aurora, CO, USA
| | - Matthew K. Wynia
- Center for Bioethics and Humanities, University of Colorado
Anschutz Medical Campus, Aurora, CO,
USA
- Colorado Clinical & Translational Sciences Institute,
University of Colorado Anschutz Medical Campus,
Aurora, CO, USA
- Division of General Internal Medicine, University of Colorado
School of Medicine, Aurora, CO,
USA
| | - Bethany M. Kwan
- Department of Family Medicine, University of Colorado
Anschutz Medical Campus, Aurora, CO,
USA
- Department of Emergency Medicine, University of Colorado
School of Medicine, Aurora, CO,
USA
- Colorado Clinical & Translational Sciences Institute,
University of Colorado Anschutz Medical Campus,
Aurora, CO, USA
| |
Collapse
|
15
|
Dylla L, Douin DJ, Cwik JE, Steinwand A, Rice JD, Jackson CL, Anderson EL, Higgins HM, Monte AA, Ginde AA. Provider Perceptions of Oxygenation Strategies for Critically Ill Trauma Patients With and Without Moderate-to-Severe Traumatic Brain Injury. Mil Med 2023; 188:166-175. [PMID: 37948260 PMCID: PMC11022338 DOI: 10.1093/milmed/usad076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 01/18/2023] [Accepted: 02/28/2023] [Indexed: 11/12/2023] Open
Abstract
BACKGROUND Hypoxia and hyperoxia (pulse oximetry [SpO2] > 96%) are associated with increased mortality in critically ill patients. However, provider practices regarding oxygenation in traumatic brain injury (TBI) patients are unknown. This study assesses views on oxygenation of critically ill trauma patients with and without TBI and how this varies between Neurological ICU (NeuroICU) and Surgical-Trauma ICU (STICU) providers. METHODS This is a cross-sectional survey of Level I trauma center's NeuroICU and STICU providers. We used Likert scales, yes-no questions, and multiple-choice case-based scenarios to characterize provider views on oxygenation with descriptive statistics to characterize responses. Significant differences regarding TBI and non-TBI patients or NeuroICU and STICU providers were determined using Fisher's exact test and a P-value of .05. RESULTS A total of 83 providers initiated the survey, and 53 providers completed it. Most providers identified a threshold SpO2 < 92% for the administration of supplemental oxygen in critically ill TBI patients. A total of 9% of providers "somewhat or completely agreed" that they were more likely to give supplemental oxygen to a critically ill trauma patient with TBI than one without TBI and the same SpO2. A total of 48% of providers selected an SpO2 < 90% as the point at which supplemental oxygen should be initiated in patients without TBI, compared to 27% of providers in patients with TBI (P < .01). This threshold for supplemental oxygen use varied by provider type for non-TBI patients, but not for TBI patients (30% NeuroICU and 69% STICU providers selected SpO2 < 90% in non-TBI, P < .05; 30% NeuroICU and 35% STICU providers selected SpO2 < 90% in TBI, P = .85). CONCLUSIONS Critical care providers at UCHealth University of Colorado Hospital approach the oxygenation of critically ill trauma patients with and without TBI differently. Specifically, critical care respondents accepted a different lower oxygen saturation threshold for TBI and non-TBI patients. NeuroICU and STICU respondents differed in their threshold for the down-titration of supplemental oxygen. Targeted education for critical care providers may reduce these discrepancies and optimize oxygen use.
Collapse
Affiliation(s)
- Layne Dylla
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - David J Douin
- Department of Anesthesiology, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Jessica E Cwik
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Aimee Steinwand
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - John D Rice
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO 80045, USA
| | - Conner L Jackson
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO 80045, USA
| | - Erin L Anderson
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Hannah M Higgins
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Andrew A Monte
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
| |
Collapse
|
16
|
Fuller RG, Rossetto MA, Paulson MW, April MD, Ginde AA, Bebarta VS, Flarity KM, Keenan S, Schauer SG. Market Analysis of Video Laryngoscopy Equipment for the Role 1 Setting. Mil Med 2023; 188:e3482-e3487. [PMID: 37338293 DOI: 10.1093/milmed/usad189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Revised: 04/17/2023] [Accepted: 05/10/2023] [Indexed: 06/21/2023] Open
Abstract
INTRODUCTION Airway compromise is the second leading cause of potentially preventable prehospital combat death. Endotracheal intubation (ETI) remains the most common role 1 airway intervention. Video laryngoscopy (VL) is superior to direct laryngoscopy (DL) for first-attempt intubation, especially in less-experienced providers and for trauma patients. The cost has been a major challenge in pushing VL technology far-forward; however, the cost of equipment continues to become more affordable. We conducted a market analysis of VL devices under $10,000 for possible options for role 1. MATERIALS AND METHODS We searched Google, PubMed, and the Food and Drug Administration database from August 2022 to January 2023 with a combination of several keywords to identify current VL market options under $10,000. After identifying relevant manufacturers, we then reviewed individual manufacturer or distributor websites for pricing data and system specifications. We noted several characteristics regarding VL device design for comparison. These include monitor features, size, modularity, system durability, battery life, and reusability. When necessary, we requested formal price quotes from respective companies. RESULTS We identified 17 VL options under $10,000 available for purchase, 14 of which were priced below $5,000 for individual units. Infium (n = 3) and Vimed Medical (n = 4) provided the largest number of unique models. VL options under $10,000 exist in both reusable and disposable modalities. These modalities included separate monitors as well as monitors attached to the VL handle. Disposable options, on a per-unit basis, cost less than reusable options. CONCLUSIONS Several VL options exist within our goal price point in both reusable and disposable options. Clinical studies assessing the technology performance of ETI and deliberate downselection are needed to identify the most cost-effective solution for role 1 dispersion.
Collapse
Affiliation(s)
- Robert G Fuller
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Center for COMBAT Research, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Marika A Rossetto
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Center for COMBAT Research, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Matthew W Paulson
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Center for COMBAT Research, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Colorado National Guard Medical Detachment, Buckley Space Force Base, CO 80112, USA
- Department of Emergency Medicine, Denver Health Medical Center, Denver, CO,USA
| | - Michael D April
- 40th Forward Resuscitative Surgical Detachment, Fort Carson, CO 80902, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Center for COMBAT Research, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Vikhyat S Bebarta
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Center for COMBAT Research, University of Colorado School of Medicine, Aurora, CO 80045, USA
- 59th Medical Wing, JBSA Lackland, TX 78236, USA
| | - Kathleen M Flarity
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Center for COMBAT Research, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Sean Keenan
- Center for COMBAT Research, University of Colorado School of Medicine, Aurora, CO 80045, USA
- Joint Trauma System, Defense Health Agency, JBSA Fort Sam Houston, TX, USA
- Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
| | - Steven G Schauer
- Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
- United States Army Institute of Surgical Research, JBSA Fort Sam Houston, TX 78234, USA
| |
Collapse
|
17
|
Surie D, Yuengling KA, DeCuir J, Zhu Y, Gaglani M, Ginde AA, Talbot HK, Casey JD, Mohr NM, Ghamande S, Gibbs KW, Files DC, Hager DN, Ali H, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Peltan ID, Brown SM, Leis AM, Khan A, Hough CL, Bender WS, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Exline MC, Lauring AS, Shapiro NI, Columbus C, Vaughn IA, Ramesh M, Safdar B, Halasa N, Chappell JD, Grijalva CG, Baughman A, Rice TW, Womack KN, Han JH, Swan SA, Mukherjee I, Lewis NM, Ellington S, McMorrow ML, Martin ET, Self WH. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years - IVY Network, 20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1083-1088. [PMID: 37796753 PMCID: PMC10564326 DOI: 10.15585/mmwr.mm7240a2] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/07/2023]
Abstract
On June 21, 2023, CDC's Advisory Committee on Immunization Practices recommended respiratory syncytial virus (RSV) vaccination for adults aged ≥60 years, offered to individual adults using shared clinical decision-making. Informed use of these vaccines requires an understanding of RSV disease severity. To characterize RSV-associated severity, 5,784 adults aged ≥60 years hospitalized with acute respiratory illness and laboratory-confirmed RSV, SARS-CoV-2, or influenza infection were prospectively enrolled from 25 hospitals in 20 U.S. states during February 1, 2022-May 31, 2023. Multivariable logistic regression was used to compare RSV disease severity with COVID-19 and influenza severity on the basis of the following outcomes: 1) standard flow (<30 L/minute) oxygen therapy, 2) high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV), 3) intensive care unit (ICU) admission, and 4) invasive mechanical ventilation (IMV) or death. Overall, 304 (5.3%) enrolled adults were hospitalized with RSV, 4,734 (81.8%) with COVID-19 and 746 (12.9%) with influenza. Patients hospitalized with RSV were more likely to receive standard flow oxygen, HFNC or NIV, and ICU admission than were those hospitalized with COVID-19 or influenza. Patients hospitalized with RSV were more likely to receive IMV or die compared with patients hospitalized with influenza (adjusted odds ratio = 2.08; 95% CI = 1.33-3.26). Among hospitalized older adults, RSV was less common, but was associated with more severe disease than COVID-19 or influenza. High disease severity in older adults hospitalized with RSV is important to consider in shared clinical decision-making regarding RSV vaccination.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - IVY Network
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC; Vanderbilt University Medical Center, Nashville, Tennessee; Baylor Scott & White Health, Temple, Texas; Texas A&M University College of Medicine, Temple, Texas; Baylor, Scott & White Health, Dallas, Texas; University of Colorado School of Medicine, Aurora, Colorado; University of Iowa, Iowa City, Iowa; Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina; Johns Hopkins Hospital, Baltimore, Maryland; Hennepin County Medical Center, Minneapolis, Minnesota; Montefiore Healthcare Center, Albert Einstein College of Medicine, New York, New York; University of Washington School of Medicine, Seattle, Washington; Baystate Medical Center, Springfield, Massachusetts; Intermountain Medical Center and University of Utah, Salt Lake City, Utah; University of Michigan School of Public Health, Ann Arbor, Michigan; Oregon Health & Science University Hospital, Portland, Oregon; Emory University School of Medicine, Atlanta, Georgia; Cleveland Clinic, Cleveland, Ohio; Stanford University School of Medicine, Stanford, California; Ronald Reagan-UCLA Medical Center, Los Angeles, California; University of Miami, Miami, Florida; Washington University, St. Louis, Missouri; The Ohio State University Wexner Medical Center, Columbus, Ohio; University of Michigan School of Medicine, Ann Arbor, Michigan; Beth Israel Deaconess Medical Center, Boston, Massachusetts; Henry Ford Health, Detroit, Michigan; Yale University School of Medicine, New Haven, Connecticut; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC
| |
Collapse
|
18
|
Prekker ME, Trent SA, Lofrano A, Russell DW, Barnes CR, Brewer JM, Doerschug KC, Gaillard JP, Gandotra S, Ginde AA, Ghamande S, Gibbs KW, Hughes CG, Janz DR, Khan A, Mitchell SH, Page DB, Rice TW, Self WH, Smith LM, Stempek SB, Vonderhaar DJ, West JR, Whitson MR, Casey JD, Semler MW, Driver BE. Laryngoscopy and Tracheal Intubation: Does Use of a Video Laryngoscope Facilitate Both Steps of the Procedure? Ann Emerg Med 2023; 82:425-431. [PMID: 37028995 PMCID: PMC11056101 DOI: 10.1016/j.annemergmed.2023.02.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 02/04/2023] [Accepted: 02/22/2023] [Indexed: 04/09/2023]
Abstract
STUDY OBJECTIVE To compare the effect of the use of a video laryngoscope versus a direct laryngoscope on each step of emergency intubation: laryngoscopy (step 1) and intubation of the trachea (step 2). METHODS In a secondary observational analysis of data from 2 multicenter, randomized trials that enrolled critically ill adults undergoing tracheal intubation but did not control for laryngoscope type (video laryngoscope vs direct laryngoscope), we fit mixed-effects logistic regression models examining the 1) the association between laryngoscope type (video laryngoscope vs direct laryngoscope) and the Cormack-Lehane grade of view and 2) the interaction between grade of view, laryngoscope type (video laryngoscope vs direct laryngoscope), and the incidence of successful intubation on the first attempt. RESULTS We analyzed 1,786 patients: 467 (26.2%) in the direct laryngoscope group and 1,319 (73.9%) in the video laryngoscope group. The use of a video laryngoscope was associated with an improved grade of view as compared with a direct laryngoscope (adjusted odds ratio for increasingly favorable grade of view 3.14, 95% confidence interval [CI] 2.47 to 3.99). Successful intubation on the first attempt occurred in 83.2% of patients in the video laryngoscope group and 72.2% of patients in the direct laryngoscope group (absolute difference 11.1%, 95% CI 6.5% to 15.6%). Video laryngoscope use modified the association between grade of view and successful intubation on the first attempt such that intubation on the first attempt was similar between video laryngoscope and direct laryngoscope at a grade 1 view and higher for video laryngoscope than direct laryngoscope at grade 2 to 4 views (P<.001 for interaction term). CONCLUSIONS Among critically ill adults undergoing tracheal intubation, the use of a video laryngoscope was associated both with a better view of the vocal cords and with a higher probability of successfully intubating the trachea when the view of the vocal cords was incomplete in this observational analysis. However, a multicenter, randomized trial directly comparing the effect of a video laryngoscope with a direct laryngoscope on the grade of view, success, and complications is needed.
Collapse
Affiliation(s)
- Matthew E Prekker
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN; Division of Pulmonary, Allergy, and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, MN.
| | - Stacy A Trent
- Department of Emergency Medicine, Denver Health, Denver, CO
| | - Arianna Lofrano
- Division of Pulmonary, Allergy, and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, MN
| | - Derek W Russell
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL; Pulmonary Section, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama
| | - Christopher R Barnes
- Department of Anesthesiology and Critical Care Medicine, University of Washington Harborview Medical Center, Seattle, WA
| | - Joseph M Brewer
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi Medical Center, Jackson, MS
| | - Kevin C Doerschug
- Department of Internal Medicine, Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa Hospital and Clinics, Iowa City, IA
| | - John P Gaillard
- Department of Anesthesiology, Section on Critical Care, Atrium Health Wake Forest Baptist, Winston-Salem, NC; Department of Emergency Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, NC
| | - Sheetal Gandotra
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO
| | - Shekhar Ghamande
- Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott & White Health, Temple, TX
| | - Kevin W Gibbs
- Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine, Winston-Salem, NC
| | - Christopher G Hughes
- Department of Anesthesiology, Division of Anesthesia Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - David R Janz
- University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary/Critical Care Medicine and Allergy/Immunology, Louisiana State University School of Medicine, New Orleans, LA
| | - Akram Khan
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Oregon Health & Science University School of Medicine, Portland, OR
| | - Steven H Mitchell
- Department of Emergency Medicine, University of Washington Harborview Medical Center, Seattle, WA
| | - David B Page
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL
| | - Todd W Rice
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Lane M Smith
- Pulmonary and Critical Care Associates, Atrium Carolinas Medical Center, Charlotte, NC
| | - Susan B Stempek
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Lahey Hospital and Medical Center, Burlington, MA
| | - Derek J Vonderhaar
- Department of Pulmonary and Critical Care Medicine, Ochsner Health, New Orleans, LA
| | - Jason R West
- Department of Emergency Medicine, Lincoln Medical Center, The Bronx, New York City, NY
| | - Micah R Whitson
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama
| | - Jonathan D Casey
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Matthew W Semler
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Brian E Driver
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN
| |
Collapse
|
19
|
Trent SA, Driver BE, Prekker ME, Barnes CR, Brewer JM, Doerschug KC, Gaillard JP, Gibbs KW, Ghamande S, Hughes CG, Janz DR, Khan A, Mitchell SH, Page DB, Rice TW, Russell DW, Self WH, Smith LM, Stempek S, Vonderhaar DJ, West JR, Whitson MR, Ginde AA, Casey JD, Semler MW. Defining Successful Intubation on the First Attempt Using Both Laryngoscope and Endotracheal Tube Insertions: A Secondary Analysis of Clinical Trial Data. Ann Emerg Med 2023; 82:432-437. [PMID: 37074254 DOI: 10.1016/j.annemergmed.2023.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 03/14/2023] [Accepted: 03/17/2023] [Indexed: 04/20/2023]
Abstract
STUDY OBJECTIVES Successful intubation on the first attempt has historically been defined as successful placement of an endotracheal tube (ETT) using a single laryngoscope insertion. More recent studies have defined successful placement of an ETT using a single laryngoscope insertion followed by a single ETT insertion. We sought to estimate the prevalence of first-attempt success using these 2 definitions and estimate their associations with the duration of intubation and serious complications. METHODS We performed a secondary analysis of data from 2 multicenter randomized trials of critically ill adults being intubated in the emergency department or ICU. We calculated the percent difference in successful intubations on the first attempt, median difference in the duration of intubation, and percent difference in the development of serious complications by definition. RESULTS The study population included 1,863 patients. Successful intubation on the first attempt decreased by 4.9% (95% confidence interval 2.5% to 7.3%) when defined as 1 laryngoscope insertion followed by 1 ETT insertion (81.2%) compared with when defined as only 1 laryngoscope insertion (86.0%). When successful intubation with 1 laryngoscope and 1 ETT insertion was compared with 1 laryngoscope and multiple ETT insertions, the median duration of intubation decreased by 35.0 seconds (95% confidence interval 8.9 to 61.1 seconds). CONCLUSION Defining successful intubation on the first attempt as placement of an ETT in the trachea using 1 laryngoscope and 1 ETT insertion identifies attempts with the shortest apneic time.
Collapse
Affiliation(s)
- Stacy A Trent
- Department of Emergency Medicine, Denver Health Medical Center, Denver, CO; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO.
| | - Brian E Driver
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN
| | - Matthew E Prekker
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN; Division of Pulmonary, Allergy, and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, MN
| | - Christopher R Barnes
- Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA
| | - Joseph M Brewer
- Division of Pulmonary, Critical Care, and Sleep Medicine and Department of Medicine, University of Mississippi Medical Center, Jackson, MS
| | | | - John P Gaillard
- Department of Emergency Medicine, Wake Forest Baptist Health, Winston-Salem, NC
| | - Kevin W Gibbs
- Department of Medicine, Section of Pulmonary, Critical Care, Allergy, and Immunologic Disease, Wake Forest Baptist Health, Winston-Salem, NC
| | - Shekhar Ghamande
- Division of Pulmonary Disease and Critical Care Medicine Baylor Scott & White, Department of Medicine, Temple, TX
| | - Christopher G Hughes
- Department of Anesthesiology, Vanderbilt University Medical Center, Division of Pulmonary, Allergy, Nashville, TN
| | - David R Janz
- Department of Pulmonary and Critical Care, University Medical Center New Orleans, New Orleans, LA; Department of Medicine, Section of Allergy/Immunology & Pulmonary/Critical Care, Louisiana State University School of Medicine, New Orleans, LA
| | - Akram Khan
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University School of Medicine, Portland, OR
| | - Steven H Mitchell
- Department of Emergency Medicine, University of Washington, Seattle, WA
| | - David B Page
- Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL
| | - Todd W Rice
- Critical Care, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Derek W Russell
- Department of Medicine, Section of Pulmonary, Birmingham Veteran's Affairs Medical Center, Birmingham, AL
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Lane M Smith
- Department of Emergency Medicine, Wake Forest Baptist Health, Winston-Salem, NC
| | - Susan Stempek
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA
| | - Derek J Vonderhaar
- Department of Pulmonary and Critical Care Medicine, Ochsner Health System, New Orleans, LA
| | - Jason R West
- Department of Emergency Medicine, Lincoln Medical Center, Bronx, NY
| | - Micah R Whitson
- Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL
| | - Adit A Ginde
- Department of Emergency Medicine, Denver Health Medical Center, Denver, CO
| | - Jonathan D Casey
- Critical Care, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Matthew W Semler
- Critical Care, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
20
|
Boulware DR, Lindsell CJ, Stewart TG, Hernandez AF, Collins S, McCarthy MW, Jayaweera D, Gentile N, Castro M, Sulkowski M, McTigue K, Felker GM, Ginde AA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Thicklin F, Wilder R, Wilson S, Shenkman E, Naggie S. Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19. N Engl J Med 2023; 389:1085-1095. [PMID: 37733308 PMCID: PMC10597427 DOI: 10.1056/nejmoa2209421] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Abstract
BACKGROUND The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization or death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear. METHODS We conducted a decentralized, double-blind, randomized, placebo-controlled platform trial in the United States to assess the use of repurposed medications in outpatients with confirmed coronavirus disease 2019 (Covid-19). Nonhospitalized adults 30 years of age or older who had at least two symptoms of acute infection that had been present for no more than 7 days before enrollment were randomly assigned to receive inhaled fluticasone furoate at a dose of 200 μg once daily for 14 days or placebo. The primary outcome was the time to sustained recovery, defined as the third of 3 consecutive days without symptoms. Key secondary outcomes included hospitalization or death by day 28 and a composite outcome of the need for an urgent-care or emergency department visit or hospitalization or death through day 28. RESULTS Of the 1407 enrolled participants who underwent randomization, 715 were assigned to receive inhaled fluticasone furoate and 692 to receive placebo, and 656 and 621, respectively, were included in the analysis. There was no evidence that the use of fluticasone furoate resulted in a shorter time to recovery than placebo (hazard ratio, 1.01; 95% credible interval, 0.91 to 1.12; posterior probability of benefit [defined as a hazard ratio >1], 0.56). A total of 24 participants (3.7%) in the fluticasone furoate group had urgent-care or emergency department visits or were hospitalized, as compared with 13 participants (2.1%) in the placebo group (hazard ratio, 1.9; 95% credible interval, 0.8 to 3.5). Three participants in each group were hospitalized, and no deaths occurred. Adverse events were uncommon in both groups. CONCLUSIONS Treatment with inhaled fluticasone furoate for 14 days did not result in a shorter time to recovery than placebo among outpatients with Covid-19 in the United States. (Funded by the National Center for Advancing Translational Sciences and others; ACTIV-6 ClinicalTrials.gov number, NCT04885530.).
Collapse
Affiliation(s)
- David R Boulware
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Christopher J Lindsell
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Thomas G Stewart
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Adrian F Hernandez
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Sean Collins
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Matthew William McCarthy
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Dushyantha Jayaweera
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Nina Gentile
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Mario Castro
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Mark Sulkowski
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Kathleen McTigue
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - G Michael Felker
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Adit A Ginde
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Sarah E Dunsmore
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Stacey J Adam
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Allison DeLong
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - George Hanna
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - April Remaly
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Florence Thicklin
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Rhonda Wilder
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Sybil Wilson
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Elizabeth Shenkman
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| | - Susanna Naggie
- From the University of Minnesota, Minneapolis (D.R.B.); Vanderbilt University Medical Center, Nashville (C.J.L., S.C.); the University of Virginia, Charlottesville (T.G.S.); the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.F.H., G.M.F., A.D., A.R., R.W., S.W., S.N.); Weill Cornell Medicine, New York (M.W.M.); the University of Miami, Miami (D.J.), and the University of Florida, Gainesville (E.S.); the Lewis Katz School of Medicine at Temple University, Philadelphia (N.G.); the University of Kansas Medical Center, Kansas City (M.C.); Johns Hopkins University, Baltimore (M.S.), and the National Center for Advancing Translational Sciences (S.E.D.) and the Foundation for the National Institutes of Health (S.J.A.), Bethesda - all in Maryland; the University of Pittsburgh Medical Center (K.M.) and the ACTIV-6 Stakeholder Advisory Committee, University of Pittsburgh (F.T.) - both in Pittsburgh; the University of Colorado Denver-Anschutz, Denver (A.A.G.); and the Biomedical Advanced Research and Development Authority, Washington, DC (G.H.)
| |
Collapse
|
21
|
Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L, Peltan ID, Lanspa M, Gilstrap DL, Mourad A, Lane K, Beitler JR, Serra AL, Garcia I, Almasri E, Fayed M, Hubel K, Harris ES, Middleton EA, Barrios MAG, Mathews KS, Goel NN, Acquah S, Mosier J, Hypes C, Salvagio Campbell E, Khan A, Hough CL, Wilson JG, Levitt JE, Duggal A, Dugar S, Goodwin AJ, Terry C, Chen P, Torbati S, Iyer N, Sandkovsky US, Johnson NJ, Robinson BRH, Matthay MA, Aggarwal NR, Douglas IS, Casey JD, Hache-Marliere M, Georges Youssef J, Nkemdirim W, Leshnower B, Awan O, Pannu S, O'Mahony DS, Manian P, Awori Hayanga JW, Wortmann GW, Tomazini BM, Miller RF, Jensen JU, Murray DD, Bickell NA, Zatakia J, Burris S, Higgs ES, Natarajan V, Dewar RL, Schechner A, Kang N, Arenas-Pinto A, Hudson F, Ginde AA, Self WH, Rogers AJ, Oldmixon CF, Morin H, Sanchez A, Weintrob AC, Cavalcanti AB, Davis-Karim A, Engen N, Denning E, Taylor Thompson B, Gelijns AC, Kan V, Davey VJ, Lundgren JD, Babiker AG, Neaton JD, Lane HC. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med 2023; 11:791-803. [PMID: 37348524 PMCID: PMC10527239 DOI: 10.1016/s2213-2600(23)00147-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 03/31/2023] [Accepted: 04/12/2023] [Indexed: 06/24/2023]
Abstract
BACKGROUND There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. METHODS TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA. Hospitalised adult patients were eligible for the study if they had acute hypoxaemic respiratory failure due to confirmed SARS-CoV-2 infection and were within 4 days of the onset of respiratory failure. Participants could be randomly assigned to both study treatments in a 2 × 2 factorial design or to just one of the agents. Participants were randomly assigned with a web-based application. For each site, randomisation was stratified by disease severity (high-flow nasal oxygen or non-invasive ventilation vs invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), and four strata were defined by remdesivir and aviptadil eligibility, as follows: (1) eligible for randomisation to aviptadil and remdesivir in the 2 × 2 factorial design; participants were equally randomly assigned (1:1:1:1) to intravenous aviptadil plus remdesivir, aviptadil plus remdesivir matched placebo, aviptadil matched placebo plus remdesvir, or aviptadil placebo plus remdesivir placebo; (2) eligible for randomisation to aviptadil only because remdesivir was started before randomisation; (3) eligible for randomisation to aviptadil only because remdesivir was contraindicated; and (4) eligible for randomisation to remdesivir only because aviptadil was contraindicated. For participants in strata 2-4, randomisation was 1:1 to the active agent or matched placebo. Aviptadil was administered as a daily 12-h infusion for 3 days, targeting 600 pmol/kg on infusion day 1, 1200 pmol/kg on day 2, and 1800 pmol/kg on day 3. Remdesivir was administered as a 200 mg loading dose, followed by 100 mg daily maintenance doses for up to a 10-day total course. For participants assigned to placebo for either agent, matched saline placebo was administered in identical volumes. For both treatment comparisons, the primary outcome, assessed at day 90, was a six-category ordinal outcome: (1) at home (defined as the type of residence before hospitalisation) and off oxygen (recovered) for at least 77 days, (2) at home and off oxygen for 49-76 days, (3) at home and off oxygen for 1-48 days, (4) not hospitalised but either on supplemental oxygen or not at home, (5) hospitalised or in hospice care, or (6) dead. Mortality up to day 90 was a key secondary outcome. The independent data and safety monitoring board recommended stopping the aviptadil trial on May 25, 2022, for futility. On June 9, 2022, the sponsor stopped the trial of remdesivir due to slow enrolment. The trial is registered with ClinicalTrials.gov, NCT04843761. FINDINGS Between April 21, 2021, and May 24, 2022, we enrolled 473 participants in the study. For the aviptadil comparison, 471 participants were randomly assigned to aviptadil or matched placebo. The modified intention-to-treat population comprised 461 participants who received at least a partial infusion of aviptadil (231 participants) or aviptadil matched placebo (230 participants). For the remdesivir comparison, 87 participants were randomly assigned to remdesivir or matched placebo and all received some infusion of remdesivir (44 participants) or remdesivir matched placebo (43 participants). 85 participants were included in the modified intention-to-treat analyses for both agents (ie, those enrolled in the 2 x 2 factorial). For the aviptadil versus placebo comparison, the median age was 57 years (IQR 46-66), 178 (39%) of 461 participants were female, and 246 (53%) were Black, Hispanic, Asian or other (vs 215 [47%] White participants). 431 (94%) of 461 participants were in an intensive care unit at baseline, with 271 (59%) receiving high-flow nasal oxygen or non-invasive ventiliation, 185 (40%) receiving invasive mechanical ventilation, and five (1%) receiving ECMO. The odds ratio (OR) for being in a better category of the primary efficacy endpoint for aviptadil versus placebo at day 90, from a model stratified by baseline disease severity, was 1·11 (95% CI 0·80-1·55; p=0·54). Up to day 90, 86 participants in the aviptadil group and 83 in the placebo group died. The cumulative percentage who died up to day 90 was 38% in the aviptadil group and 36% in the placebo group (hazard ratio 1·04, 95% CI 0·77-1·41; p=0·78). The primary safety outcome of death, serious adverse events, organ failure, serious infection, or grade 3 or 4 adverse events up to day 5 occurred in 146 (63%) of 231 patients in the aviptadil group compared with 129 (56%) of 230 participants in the placebo group (OR 1·40, 95% CI 0·94-2·08; p=0·10). INTERPRETATION Among patients with COVID-19-associated acute hypoxaemic respiratory failure, aviptadil did not significantly improve clinical outcomes up to day 90 when compared with placebo. The smaller than planned sample size for the remdesivir trial did not permit definitive conclusions regarding safety or efficacy. FUNDING National Institutes of Health.
Collapse
Affiliation(s)
- Samuel M Brown
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Salt Lake City, UT, USA; Department of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA.
| | - Christina E Barkauskas
- Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC, USA
| | - Birgit Grund
- School of Statistics, University of Minnesota, Minneapolis, MN, USA
| | - Shweta Sharma
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA
| | | | - Lindsay Leither
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Salt Lake City, UT, USA; Department of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA
| | - Ithan D Peltan
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Salt Lake City, UT, USA; Department of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA
| | - Michael Lanspa
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Salt Lake City, UT, USA; Department of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA
| | - Daniel L Gilstrap
- Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC, USA
| | - Ahmad Mourad
- Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA
| | - Kathleen Lane
- Surgical Office of Clinical Research, Cardiothoracic Surgical Division, Duke University School of Medicine, Durham, NC, USA
| | - Jeremy R Beitler
- Columbia Respiratory Critical Care Trials Group and Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York, NY, USA; Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, NY, USA
| | - Alexis L Serra
- Columbia Respiratory Critical Care Trials Group and Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York, NY, USA; Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, NY, USA
| | - Ivan Garcia
- Columbia Respiratory Critical Care Trials Group and Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York, NY, USA; Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, NY, USA
| | - Eyad Almasri
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, UCSF Fresno, Fresno, CA, USA
| | - Mohamed Fayed
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, UCSF Fresno, Fresno, CA, USA
| | - Kinsley Hubel
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, UCSF Fresno, Fresno, CA, USA
| | - Estelle S Harris
- Department of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA
| | - Elizabeth A Middleton
- Department of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA
| | - Macy A G Barrios
- Department of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA
| | - Kusum S Mathews
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Neha N Goel
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Samuel Acquah
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jarrod Mosier
- Department of Emergency Medicine, University of Arizona College of Medicine, Tucson, AZ; Division of Pulmonary, Allergy, Critical Care and Sleep, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ; Banner University Medical Center- Tucson, Tucson, AZ, USA
| | - Cameron Hypes
- Department of Emergency Medicine, University of Arizona College of Medicine, Tucson, AZ; Division of Pulmonary, Allergy, Critical Care and Sleep, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ
| | | | - Akram Khan
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Catherine L Hough
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Jennifer G Wilson
- Department of Emergency Medicine, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Joseph E Levitt
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Abhijit Duggal
- Department of Critical Care, Respiratory Institute, Cleveland Clinic, Cleveland OH, USA
| | - Siddharth Dugar
- Department of Critical Care, Respiratory Institute, Cleveland Clinic, Cleveland OH, USA
| | - Andrew J Goodwin
- Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA
| | - Charles Terry
- Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA
| | - Peter Chen
- Women's Guild Lung Institute, Department of Medicine and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Sam Torbati
- Department of Emergency Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Nithya Iyer
- Division of of Pulmonary/Critical Care and Sleep Medicine, Department of Medicine, Baylor University Medical Center, Dallas, TX, USA; Texas A&M School of Medicine, Dallas, TX, USA
| | - Uriel S Sandkovsky
- Division of Infectious Diseases, Department of Medicine, Baylor University Medical Center, Dallas, TX, USA
| | - Nicholas J Johnson
- Department of Emergency Medicine, University of Washington Harborview Medical Center, Seattle, WA, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Harborview Medical Center, Seattle, WA, USA
| | - Bryce R H Robinson
- Department of Surgery, University of Washington Harborview Medical Center, Seattle, WA, USA
| | - Michael A Matthay
- Cardiovascular Research Institute and Departments of Medicine and Anesthesia, University of California-San Francisco, San Francisco, CA, USA
| | - Neil R Aggarwal
- Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Ivor S Douglas
- Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Medicine, Denver Health Medical Center, Denver, CO, USA
| | - Jonathan D Casey
- Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Manuel Hache-Marliere
- Jacobi Medical Center, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA
| | - J Georges Youssef
- Department of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, NY, USA; JC Walter Jr Transplant Center Advanced Lung Diseases Program, Houston Methodist Hospital, Houston, TX, USA
| | - William Nkemdirim
- Jacobi Medical Center, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA
| | - Brad Leshnower
- Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA, USA
| | - Omar Awan
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Disorders Medicine, VA Medical Center and George Washington University, Washington, DC, USA
| | - Sonal Pannu
- Department of Medicine, Division of Pulmonary Critical Care and Sleep, Ohio State University, Columbus, OH, USA
| | | | - Prasad Manian
- Division of Pulmonary and Critical Medicine, Baylor College of Medicine, Texas Heart Institute, Houston, TX, USA
| | - J W Awori Hayanga
- Department of Cardiovascular and Thoracic Surgery. Heart and Vascular Institute, West Virginia University, Morgantown, WV, USA
| | - Glenn W Wortmann
- Infectious Diseases Section, MedStar Washington Hospital Center and Georgetown University, Washington, DC, USA
| | - Bruno M Tomazini
- Brazilian Research in Intensive Care Network (BRICNet), São Paulo, Brazil; HCor Research Institute, São Paulo, Brazil
| | - Robert F Miller
- Institute for Global Health, University College London, London, UK
| | - Jens-Ulrik Jensen
- Section of Respiratory Medicine, Department of Medicine, Herlev-Gentofte Hospital, Hellerup, Denmark; CHIP, Centre of Excellence for Health, Immunity and Infections, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Daniel D Murray
- CHIP, Centre of Excellence for Health, Immunity and Infections, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Nina A Bickell
- Department of Population Health Science and Policy and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jigna Zatakia
- Department of Medicine, Division of Pulmonary Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Sarah Burris
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Elizabeth S Higgs
- National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Ven Natarajan
- Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Robin L Dewar
- Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Adam Schechner
- Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Nayon Kang
- National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Alejandro Arenas-Pinto
- Institute for Global Health, University College London, London, UK; The Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK
| | - Fleur Hudson
- The Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Angela J Rogers
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Cathryn F Oldmixon
- Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA
| | - Haley Morin
- Stanford University School of Medicine, Palo Alto, CA, USA
| | - Adriana Sanchez
- Infectious Diseases Section, Veteran Affairs Medical Center, Washington, DC, USA
| | - Amy C Weintrob
- Infectious Diseases Section, Veteran Affairs Medical Center, Washington, DC, USA
| | | | - Anne Davis-Karim
- Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Office of Research & Development, Department of Veterans Affairs, Albuquerque, NM, USA
| | - Nicole Engen
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA
| | - Eileen Denning
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA
| | - B Taylor Thompson
- Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital and Harvard Medical School; Boston, MA, USA
| | - Annetine C Gelijns
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Virginia Kan
- Infectious Diseases Section, Veteran Affairs Medical Center, Washington, DC, USA
| | - Victoria J Davey
- United States Department of Veterans Affairs; Washington, DC, USA
| | - Jens D Lundgren
- Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Abdel G Babiker
- The Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK
| | - James D Neaton
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA
| | - H Clifford Lane
- National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| |
Collapse
|
22
|
Han JH, Jackson JC, Orun OM, Brown SM, Casey JD, Clark L, Collins SP, Cordero K, Ginde AA, Gong MN, Hough CL, Iwashyna TJ, Kiehl AL, Lauck A, Leither LM, Lindsell CJ, Patel MB, Raman R, Rice TW, Ringwood NJ, Sheppard KL, Semler MW, Thompson BT, Ely EW, Self WH. Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19. Influenza Other Respir Viruses 2023; 17:e13197. [PMID: 37752063 PMCID: PMC10522479 DOI: 10.1111/irv.13197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 08/22/2023] [Accepted: 08/23/2023] [Indexed: 09/28/2023] Open
Abstract
BACKGROUND We sought to identify potentially modifiable in-hospital factors associated with global cognition, post-traumatic stress disorder (PTSD) symptoms, and depression symptoms at 12 months. METHODS This was a multi-center prospective cohort study in adult hospitalized patients with acute COVID-19. The following in-hospital factors were assessed: delirium; frequency of in-person and virtual visits by friends and family; and hydroxychloroquine, corticosteroid, and remdesivir administration. Twelve-month global cognition was characterized by the MOCA-Blind. Twelve-month PTSD and depression were characterized using the PTSD Checklist for the DSM-V and Hospital Anxiety Depression Scale, respectively. FINDINGS Two hundred three patients completed the 12-month follow-up assessments. Remdesivir use was associated with significantly higher cognition at 12 months based on the MOCA-Blind (adjusted odds ratio [aOR] = 1.98, 95% CI: 1.06, 3.70). Delirium was associated with worsening 12-month PTSD (aOR = 3.44, 95% CI: 1.89, 6.28) and depression (aOR = 2.18, 95% CI: 1.23, 3.84) symptoms. Multiple virtual visits per day during hospitalization was associated with lower 12-month depression symptoms compared to those with less than daily virtual visits (aOR = 0.40, 95% CI: 0.19, 0.85). CONCLUSION Potentially modifiable factors associated with better long-term outcomes included remdesivir use (associated with better cognitive function), avoidance of delirium (associated with less PTSD and depression symptoms), and increased virtual interactions with friends and family (associated with less depression symptoms).
Collapse
Affiliation(s)
- Jin H. Han
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
- Geriatric Research, Education, and Clinical Center (GRECC)Tennessee Valley Healthcare SystemNashvilleTennesseeUSA
- Department of Emergency MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - James C. Jackson
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
- Geriatric Research, Education, and Clinical Center (GRECC)Tennessee Valley Healthcare SystemNashvilleTennesseeUSA
- Division of Allergy, Pulmonary, and Critical Care, Department of MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Onur M. Orun
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of BiostatisticsVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Samuel M. Brown
- Division of Pulmonary/Critical Care Medicine, Department of MedicineIntermountain Medical Center and the University of UtahSalt Lake CityUtahUSA
| | - Jonathan D. Casey
- Division of Allergy, Pulmonary, and Critical Care, Department of MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Lindsay Clark
- Division of Geriatrics and GerontologyUniversity of Wisconsin School of Medicine and Public HealthMadisonWisconsinUSA
- Geriatric Research, Education, and Clinical Center (GRECC)William S Middleton Memorial Veterans HospitalMadisonWisconsinUSA
| | - Sean P. Collins
- Geriatric Research, Education, and Clinical Center (GRECC)Tennessee Valley Healthcare SystemNashvilleTennesseeUSA
- Department of Emergency MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Kemberlyne Cordero
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Adit A. Ginde
- Department of Emergency MedicineUniversity of Colorado School of MedicineAuroraColoradoUSA
| | - Michelle N. Gong
- Division of Critical Care, Division of Pulmonary Medicine, Department of MedicineAlbert Einstein College of MedicineBronxNew YorkUSA
| | - Catherine L. Hough
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of MedicineOregon Health & Science UniversityPortlandOregonUSA
| | - Theodore J. Iwashyna
- Division of Pulmonary and Critical Care, Department of MedicineJohns Hopkins UniversityBaltimoreMarylandUSA
- Health Policy & Management in the Bloomberg School of Public HealthJohns Hopkins UniversityBaltimoreMarylandUSA
| | - Amy L. Kiehl
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Alana Lauck
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Lindsay M. Leither
- Division of Pulmonary/Critical Care Medicine, Department of MedicineIntermountain Medical Center and the University of UtahSalt Lake CityUtahUSA
| | | | - Mayur B. Patel
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
- Geriatric Research, Education, and Clinical Center (GRECC)Tennessee Valley Healthcare SystemNashvilleTennesseeUSA
- Division of Acute Care Surgery, Department of Surgery, Section of Surgical SciencesVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Rameela Raman
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of BiostatisticsVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Todd W. Rice
- Division of Allergy, Pulmonary, and Critical Care, Department of MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
- Vanderbilt Institute for Clinical and Translational Research (VICTR)Vanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Nancy J. Ringwood
- Division of Pulmonary and Critical Care MedicineMassachusetts General HospitalBostonMassachusettsUSA
| | - Karen L. Sheppard
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Matthew W. Semler
- Division of Allergy, Pulmonary, and Critical Care, Department of MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - B. Taylor Thompson
- Division of Pulmonary and Critical Care MedicineMassachusetts General HospitalBostonMassachusettsUSA
| | - E. Wesley Ely
- Critical Illness, Brain Dysfunction, and Survivorship CenterVanderbilt University Medical CenterNashvilleTennesseeUSA
- Geriatric Research, Education, and Clinical Center (GRECC)Tennessee Valley Healthcare SystemNashvilleTennesseeUSA
- Division of Allergy, Pulmonary, and Critical Care, Department of MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Wesley H. Self
- Department of Emergency MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
- Division of Acute Care Surgery, Department of Surgery, Section of Surgical SciencesVanderbilt University Medical CenterNashvilleTennesseeUSA
- Vanderbilt Institute for Clinical and Translational Research (VICTR)Vanderbilt University Medical CenterNashvilleTennesseeUSA
| | | |
Collapse
|
23
|
Young-Xu Y, Epstein L, Marconi VC, Davey V, Korves C, Zwain G, Smith J, Cunningham F, Bonomo RA, Ginde AA. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data. mBio 2023; 14:e0102423. [PMID: 37535398 PMCID: PMC10470809 DOI: 10.1128/mbio.01024-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 06/22/2023] [Indexed: 08/04/2023] Open
Abstract
Little is known regarding the effectiveness of tixagevimab/cilgavimab in preventing SARS-CoV-2 infection in vaccinated immunocompromised patients, particularly after the emergence of the Omicron variant. In this retrospective cohort study with exact matching and propensity score adjustment within the U.S. Department of Veterans Affairs (VA) healthcare system, we selected immunocompromised veterans age ≥18 years as of 1 January 2022, receiving VA healthcare. We compared a cohort of 1,878 patients treated with at least one dose of intramuscular tixagevimab/cilgavimab to 7,014 matched controls selected from patients who met study criteria but were not treated. Patients were followed through 15 June 2022, or until death, whichever occurred earlier. The primary outcome was a composite of SARS-CoV-2 infection, COVID-19-related hospitalization, and all-cause mortality. We used Cox proportional hazards modeling to estimate the hazard ratios (HRs) and 95% CI for the association between receipt of tixagevimab/cilgavimab and outcomes. Most (73%) tixagevimab/cilgavimab recipients were ≥65 years old, and 80% had ≥3 mRNA vaccine doses or two doses of Ad26.COV2. Compared to matched controls, recipients had a lower incidence of the composite COVID-19 outcome (49/1,878 [2.6%] versus 312/7,014 [4.4%]; HR 0.35; 95% CI, 0.24-0.52), and individually SARS-CoV-2 infection (HR 0.44; 95% CI, 0.22-0.88), COVID-19 hospitalization (HR 0.24; 95% CI, 0.10-0.59), and all-cause mortality (HR 0.32; 95% CI, 0.19-0.55). In conclusion, tixagevimab/cilgavimab was associated with lower rates of SARS-CoV-2 infection and severe COVID-19 during the Omicron BA.1, BA.2, and BA.2.12.1 surge. IMPORTANCE SARS-CoV-2 remains an ongoing global health crisis that justifies continued efforts to validate and expand, when possible, knowledge on the efficacy of available vaccines and treatments. Clinical trials have been limited due to fast tracking of medications for mitigation of the COVID-19 pandemic for the general population. We present a real-world analysis, using electronic health record data, of the effectiveness of tixagevimab/cilgavimab for the prevention of COVID-19 infection in the unique population of U.S. veterans. Unlike those in the PROVENT clinical trial from which the emergency use authorization for tixagevimab/cilgavimab as a preventative treatment arose, the veterans population is highly immunocompromised and nearly 96% totally vaccinated. These demographics allowed us to analyze the effectiveness of tixagevimab/cilgavimab in preventing COVID-19 under different conditions in a more fragile population than that of the initial clinical trial.
Collapse
Affiliation(s)
- Yinong Young-Xu
- US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, Illinois, USA
| | - Lauren Epstein
- Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Vincent C. Marconi
- Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Victoria Davey
- US Department of Veteran’s Affairs, Office of Research and Development, Washington, DC, USA
| | - Caroline Korves
- White River Junction Veterans Affairs Medical Center, CEP, White River Junction, Vermont, USA
| | - Gabrielle Zwain
- White River Junction Veterans Affairs Medical Center, CEP, White River Junction, Vermont, USA
| | - Jeremy Smith
- White River Junction Veterans Affairs Medical Center, CEP, White River Junction, Vermont, USA
| | - Fran Cunningham
- US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, Illinois, USA
| | - Robert A. Bonomo
- US Department of Veterans Affairs, VA SHIELD, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA
- Case Western Reserve University, Cleveland, Ohio, USA
| | - Adit A. Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| |
Collapse
|
24
|
Kojima N, Adams K, Self WH, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Prekker ME, Peltan ID, Brown SM, Hager DN, Ali H, Gong MN, Mohamed A, Exline MC, Khan A, Wilson JG, Qadir N, Chang SY, Ginde AA, Withers CA, Mohr NM, Mallow C, Martin ET, Lauring AS, Johnson NJ, Casey JD, Stubblefield WB, Gibbs KW, Kwon JH, Baughman A, Chappell JD, Hart KW, Jones ID, Rhoads JP, Swan SA, Womack KN, Zhu Y, Surie D, McMorrow ML, Patel MM, Tenforde MW. Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022. Clin Infect Dis 2023; 77:547-557. [PMID: 37255285 PMCID: PMC10526883 DOI: 10.1093/cid/ciad276] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Indexed: 06/01/2023] Open
Abstract
INTRODUCTION Understanding the changing epidemiology of adults hospitalized with coronavirus disease 2019 (COVID-19) informs research priorities and public health policies. METHODS Among adults (≥18 years) hospitalized with laboratory-confirmed, acute COVID-19 between 11 March 2021, and 31 August 2022 at 21 hospitals in 18 states, those hospitalized during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron-predominant period (BA.1, BA.2, BA.4/BA.5) were compared to those from earlier Alpha- and Delta-predominant periods. Demographic characteristics, biomarkers within 24 hours of admission, and outcomes, including oxygen support and death, were assessed. RESULTS Among 9825 patients, median (interquartile range [IQR]) age was 60 years (47-72), 47% were women, and 21% non-Hispanic Black. From the Alpha-predominant period (Mar-Jul 2021; N = 1312) to the Omicron BA.4/BA.5 sublineage-predominant period (Jun-Aug 2022; N = 1307): the percentage of patients who had ≥4 categories of underlying medical conditions increased from 11% to 21%; those vaccinated with at least a primary COVID-19 vaccine series increased from 7% to 67%; those ≥75 years old increased from 11% to 33%; those who did not receive any supplemental oxygen increased from 18% to 42%. Median (IQR) highest C-reactive protein and D-dimer concentration decreased from 42.0 mg/L (9.9-122.0) to 11.5 mg/L (2.7-42.8) and 3.1 mcg/mL (0.8-640.0) to 1.0 mcg/mL (0.5-2.2), respectively. In-hospital death peaked at 12% in the Delta-predominant period and declined to 4% during the BA.4/BA.5-predominant period. CONCLUSIONS Compared to adults hospitalized during early COVID-19 variant periods, those hospitalized during Omicron-variant COVID-19 were older, had multiple co-morbidities, were more likely to be vaccinated, and less likely to experience severe respiratory disease, systemic inflammation, coagulopathy, and death.
Collapse
Affiliation(s)
- Noah Kojima
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Katherine Adams
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Wesley H Self
- Department of Emergency Medicine and Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Manjusha Gaglani
- Department of Pediatrics, Baylor Scott & White Health and Texas A&M University College of Medicine, Temple and Dallas, Texas, USA
| | - Tresa McNeal
- Department of Medical Education, Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Shekhar Ghamande
- Department of Medical Education, Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Jay S Steingrub
- Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA
| | - Nathan I Shapiro
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Abhijit Duggal
- Department of Medicine, Cleveland Clinic, Cleveland, Ohio, USA
| | | | - Matthew E Prekker
- Department of Emergency Medicine and Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
| | - Ithan D Peltan
- Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City, Utah, USA
| | - Samuel M Brown
- Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City, Utah, USA
| | - David N Hager
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Harith Ali
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Michelle N Gong
- Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Amira Mohamed
- Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Matthew C Exline
- Department of Medicine, The Ohio State University, Columbus, Ohio, USA
| | - Akram Khan
- Department of Medicine, Oregon Health and Sciences University, Portland, Oregon, USA
| | - Jennifer G Wilson
- Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Nida Qadir
- Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA
| | - Steven Y Chang
- Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Cori A Withers
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Nicholas M Mohr
- Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA
| | | | - Emily T Martin
- School of Public Health, University of Michigan, Ann Arbor, Michigan, USA
| | - Adam S Lauring
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
| | - Nicholas J Johnson
- Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA
| | - Jonathan D Casey
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - William B Stubblefield
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kevin W Gibbs
- Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Jennie H Kwon
- Department of Medicine, Washington University, St. Louis, Missouri, USA
| | - Adrienne Baughman
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kimberly W Hart
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Ian D Jones
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Jillian P Rhoads
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Sydney A Swan
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kelsey N Womack
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Yuwei Zhu
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Diya Surie
- Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Meredith L McMorrow
- Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Manish M Patel
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Mark W Tenforde
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
25
|
Dimcheff DE, Blair CN, Zhu Y, Chappell JD, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Frosch AEP, Peltan ID, Hager DN, Gong MN, Exline MC, Khan A, Wilson JG, Qadir N, Ginde AA, Douin DJ, Mohr NM, Mallow C, Martin ET, Johnson NJ, Casey JD, Stubblefield WB, Gibbs KW, Kwon JH, Talbot HK, Halasa N, Grijalva CG, Baughman A, Womack KN, Hart KW, Swan SA, Surie D, Thornburg NJ, McMorrow ML, Self WH, Lauring AS. Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. J Infect Dis 2023; 228:235-244. [PMID: 36883903 PMCID: PMC10420395 DOI: 10.1093/infdis/jiad061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Accepted: 03/06/2023] [Indexed: 03/09/2023] Open
Abstract
BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic and subgenomic RNA levels are frequently used as a correlate of infectiousness. The impact of host factors and SARS-CoV-2 lineage on RNA viral load is unclear. METHODS Total nucleocapsid (N) and subgenomic N (sgN) RNA levels were measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in specimens from 3204 individuals hospitalized with coronavirus disease 2019 (COVID-19) at 21 hospitals. RT-qPCR cycle threshold (Ct) values were used to estimate RNA viral load. The impact of time of sampling, SARS-CoV-2 variant, age, comorbidities, vaccination, and immune status on N and sgN Ct values were evaluated using multiple linear regression. RESULTS Mean Ct values at presentation for N were 24.14 (SD 4.53) for non-variants of concern, 25.15 (SD 4.33) for Alpha, 25.31 (SD 4.50) for Delta, and 26.26 (SD 4.42) for Omicron. N and sgN RNA levels varied with time since symptom onset and infecting variant but not with age, comorbidity, immune status, or vaccination. When normalized to total N RNA, sgN levels were similar across all variants. CONCLUSIONS RNA viral loads were similar among hospitalized adults, irrespective of infecting variant and known risk factors for severe COVID-19. Total N and subgenomic RNA N viral loads were highly correlated, suggesting that subgenomic RNA measurements add little information for the purposes of estimating infectivity.
Collapse
Affiliation(s)
- Derek E Dimcheff
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Christopher N Blair
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Yuwei Zhu
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Manjusha Gaglani
- Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Tresa McNeal
- Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Shekhar Ghamande
- Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Jay S Steingrub
- Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA
| | - Nathan I Shapiro
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Abhijit Duggal
- Department of Medicine, Cleveland Clinic, Cleveland, Ohio, USA
| | | | - Anne E P Frosch
- Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
| | - Ithan D Peltan
- Department of Medicine, Intermountain Medical Center, Murray, Utah, USA
- Department of Medicine, University of Utah, Salt Lake City, Utah, USA
| | - David N Hager
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Michelle N Gong
- Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Matthew C Exline
- Department of Medicine, The Ohio State University, Columbus, Ohio, USA
| | - Akram Khan
- Department of Medicine, Oregon Health and Sciences University, Portland, Oregon, USA
| | - Jennifer G Wilson
- Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Nida Qadir
- Department of Medicine, University of California Los Angeles, Los Angeles, California, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - David J Douin
- Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Nicholas M Mohr
- Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA
| | | | - Emily T Martin
- School of Public Health, University of Michigan, Ann Arbor, Michigan, USA
| | - Nicholas J Johnson
- Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA
| | - Jonathan D Casey
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - William B Stubblefield
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kevin W Gibbs
- Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Jennie H Kwon
- Department of Medicine, Washington University, St Louis, Missouri, USA
| | - H Keipp Talbot
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Natasha Halasa
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Carlos G Grijalva
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adrienne Baughman
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kelsey N Womack
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kimberly W Hart
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Sydney A Swan
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Diya Surie
- COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Natalie J Thornburg
- COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Meredith L McMorrow
- COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adam S Lauring
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
| | | |
Collapse
|
26
|
Prekker ME, Driver BE, Trent SA, Resnick-Ault D, Seitz KP, Russell DW, Gaillard JP, Latimer AJ, Ghamande SA, Gibbs KW, Vonderhaar DJ, Whitson MR, Barnes CR, Walco JP, Douglas IS, Krishnamoorthy V, Dagan A, Bastman JJ, Lloyd BD, Gandotra S, Goranson JK, Mitchell SH, White HD, Palakshappa JA, Espinera A, Page DB, Joffe A, Hansen SJ, Hughes CG, George T, Herbert JT, Shapiro NI, Schauer SG, Long BJ, Imhoff B, Wang L, Rhoads JP, Womack KN, Janz DR, Self WH, Rice TW, Ginde AA, Casey JD, Semler MW. Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults. N Engl J Med 2023; 389:418-429. [PMID: 37326325 DOI: 10.1056/nejmoa2301601] [Citation(s) in RCA: 35] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
BACKGROUND Whether video laryngoscopy as compared with direct laryngoscopy increases the likelihood of successful tracheal intubation on the first attempt among critically ill adults is uncertain. METHODS In a multicenter, randomized trial conducted at 17 emergency departments and intensive care units (ICUs), we randomly assigned critically ill adults undergoing tracheal intubation to the video-laryngoscope group or the direct-laryngoscope group. The primary outcome was successful intubation on the first attempt. The secondary outcome was the occurrence of severe complications during intubation; severe complications were defined as severe hypoxemia, severe hypotension, new or increased vasopressor use, cardiac arrest, or death. RESULTS The trial was stopped for efficacy at the time of the single preplanned interim analysis. Among 1417 patients who were included in the final analysis (91.5% of whom underwent intubation that was performed by an emergency medicine resident or a critical care fellow), successful intubation on the first attempt occurred in 600 of the 705 patients (85.1%) in the video-laryngoscope group and in 504 of the 712 patients (70.8%) in the direct-laryngoscope group (absolute risk difference, 14.3 percentage points; 95% confidence interval [CI], 9.9 to 18.7; P<0.001). A total of 151 patients (21.4%) in the video-laryngoscope group and 149 patients (20.9%) in the direct-laryngoscope group had a severe complication during intubation (absolute risk difference, 0.5 percentage points; 95% CI, -3.9 to 4.9). Safety outcomes, including esophageal intubation, injury to the teeth, and aspiration, were similar in the two groups. CONCLUSIONS Among critically ill adults undergoing tracheal intubation in an emergency department or ICU, the use of a video laryngoscope resulted in a higher incidence of successful intubation on the first attempt than the use of a direct laryngoscope. (Funded by the U.S. Department of Defense; DEVICE ClinicalTrials.gov number, NCT05239195.).
Collapse
Affiliation(s)
- Matthew E Prekker
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Brian E Driver
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Stacy A Trent
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Daniel Resnick-Ault
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Kevin P Seitz
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Derek W Russell
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - John P Gaillard
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Andrew J Latimer
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Shekhar A Ghamande
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Kevin W Gibbs
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Derek J Vonderhaar
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Micah R Whitson
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Christopher R Barnes
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Jeremy P Walco
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Ivor S Douglas
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Vijay Krishnamoorthy
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Alon Dagan
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Jill J Bastman
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Bradley D Lloyd
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Sheetal Gandotra
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Jordan K Goranson
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Steven H Mitchell
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Heath D White
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Jessica A Palakshappa
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Alyssa Espinera
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - David B Page
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Aaron Joffe
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Sydney J Hansen
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Christopher G Hughes
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Tobias George
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - J Taylor Herbert
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Nathan I Shapiro
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Steven G Schauer
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Brit J Long
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Brant Imhoff
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Li Wang
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Jillian P Rhoads
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Kelsey N Womack
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - David R Janz
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Wesley H Self
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Todd W Rice
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Adit A Ginde
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Jonathan D Casey
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| | - Matthew W Semler
- From the Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine (M.E.P., S.J.H.), and the Department of Emergency Medicine (M.E.P., B.E.D.), Hennepin County Medical Center, Minneapolis; the Department of Emergency Medicine (S.A.T.) and the Division of Pulmonary, Critical Care, and Sleep Medicine (I.S.D., T.G.), Denver Health Medical Center, Denver, and the Department of Emergency Medicine (S.A.T., D.R.-A., J.J.B., A.A.G.) and the Department of Medicine, Division of Pulmonary and Critical Care Medicine (I.S.D.), University of Colorado School of Medicine, Aurora; the Department of Medicine, Division of Pulmonary and Critical Care Medicine (K.P.S., T.W.R., J.D.C., M.W.S.), the Departments of Anesthesiology (J.P.W., C.G.H.), Emergency Medicine (B.D.L., W.H.S.), and Biostatistics (B.I., L.W.), and the Vanderbilt Institute for Clinical and Translational Research (J.P.R., K.N.W., W.H.S., T.W.R., M.W.S.), Vanderbilt University Medical Center, Nashville; the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine (D.W.R., M.R.W., S.G., D.B.P.), and the Department of Emergency Medicine (M.R.W.), University of Alabama at Birmingham Heersink School of Medicine, and the Pulmonary Section, Birmingham Veterans Affairs Medical Center (D.W.R.) - both in Birmingham; the Department of Anesthesiology, Section on Critical Care (J.P.G.), and the Department of Emergency Medicine (J.P.G., J.K.G.), Atrium Health Wake Forest Baptist, and the Section on Pulmonary, Critical Care, Allergy, and Immunology, Wake Forest School of Medicine (K.W.G., J.A.P.), Winston-Salem, and the Department of Anesthesiology, Duke University School of Medicine, Durham (V.K., J.T.H.) - all in North Carolina; the Departments of Emergency Medicine (A.J.L., S.H.M.) and Anesthesiology and Critical Care Medicine (C.R.B., A.J.), University of Washington Harborview Medical Center, Seattle; the Department of Medicine, Division of Pulmonary Disease, Critical Care, and Sleep Medicine, Baylor Scott and White Health, Temple (S.A.G., H.D.W.), and the U.S. Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston (S.G.S.), and the 59th Medical Wing, U.S. Air Force, Fort Sam Houston (B.J.L.), San Antonio - all in Texas; the Department of Pulmonary and Critical Care Medicine, Ochsner Health (D.J.V., A.E.), and University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary, Critical Care Medicine, and Allergy and Immunology, Louisiana State University School of Medicine (D.R.J.) - all in New Orleans; and the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston (A.D., N.I.S.)
| |
Collapse
|
27
|
Fuchita M, Pattee J, Russell DW, Driver BE, Prekker ME, Barnes CR, Brewer JM, Doerschug KC, Gaillard JP, Gandotra S, Ghamande S, Gibbs KW, Hughes CG, Janz DR, Khan A, Mitchell SH, Page DB, Rice TW, Self WH, Smith LM, Stempek SB, Trent SA, Vonderhaar DJ, West JR, Whitson MR, Williamson K, Semler MW, Casey JD, Ginde AA. Prophylactic Administration of Vasopressors Prior to Emergency Intubation in Critically Ill Patients: A Secondary Analysis of Two Multicenter Clinical Trials. Crit Care Explor 2023; 5:e0946. [PMID: 37457916 PMCID: PMC10344527 DOI: 10.1097/cce.0000000000000946] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/18/2023] Open
Abstract
Hypotension affects approximately 40% of critically ill patients undergoing emergency intubation and is associated with an increased risk of death. The objective of this study was to examine the association between prophylactic vasopressor administration and the incidence of peri-intubation hypotension and other clinical outcomes. DESIGN A secondary analysis of two multicenter randomized clinical trials. The clinical effect of prophylactic vasopressor administration was estimated using a one-to-one propensity-matched cohort of patients with and without prophylactic vasopressors. SETTING Seven emergency departments and 17 ICUs across the United States. PATIENTS One thousand seven hundred ninety-eight critically ill patients who underwent emergency intubation at the study sites between February 1, 2019, and May 24, 2021. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS The primary outcome was peri-intubation hypotension defined as a systolic blood pressure less than 90 mm Hg occurring between induction and 2 minutes after tracheal intubation. A total of 187 patients (10%) received prophylactic vasopressors prior to intubation. Compared with patients who did not receive prophylactic vasopressors, those who did were older, had higher Acute Physiology and Chronic Health Evaluation II scores, were more likely to have a diagnosis of sepsis, had lower pre-induction systolic blood pressures, and were more likely to be on continuous vasopressor infusions prior to intubation. In our propensity-matched cohort, prophylactic vasopressor administration was not associated with reduced risk of peri-intubation hypotension (41% vs 32%; p = 0.08) or change in systolic blood pressure from baseline (-12 vs -11 mm Hg; p = 0.66). CONCLUSIONS The administration of prophylactic vasopressors was not associated with a lower incidence of peri-intubation hypotension in our propensity-matched analysis. To address potential residual confounding, randomized clinical trials should examine the effect of prophylactic vasopressor administration on peri-intubation outcomes.
Collapse
Affiliation(s)
- Mikita Fuchita
- Department of Anesthesiology, Division of Critical Care, University of Colorado Anschutz Medical Campus, Aurora, CO
| | - Jack Pattee
- Department of Biostatistics & Informatics, Center for Innovative Design & Analysis, Colorado School of Public Health, Aurora, CO
| | - Derek W Russell
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL
- Pulmonary Section, Birmingham Veterans Affairs Medical Center, Birmingham, AL
| | - Brian E Driver
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN
| | - Matthew E Prekker
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, MN
| | - Christopher R Barnes
- Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA
| | - Joseph M Brewer
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi Medical Center, Jackson, MS
| | | | - John P Gaillard
- Department of Emergency Medicine, Wake Forest School of Medicine, Winston-Salem, NC
- Department of Anesthesiology, Section on Critical Care, Wake Forest School of Medicine, Winston-Salem, NC
| | - Sheetal Gandotra
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL
| | - Shekhar Ghamande
- Department of Medicine, Division of Pulmonary Disease and Critical Care Medicine, Baylor Scott & White Medical Center, Temple, TX
| | - Kevin W Gibbs
- Department of Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Disease, Wake Forest School of Medicine, Winston-Salem, NC
| | - Christopher G Hughes
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN
| | - David R Janz
- University Medical Center New Orleans, New Orleans, LA
- Department of Medicine, Section of Pulmonary/Critical Care Medicine and Allergy/Immunology, Louisiana State University School of Medicine, New Orleans, LA
| | - Akram Khan
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Oregon Health & Science University School of Medicine, Portland, OR
| | - Steven H Mitchell
- Department of Emergency Medicine, University of Washington, Seattle, WA
| | - David B Page
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL
| | - Todd W Rice
- Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN
| | - Lane M Smith
- Department of Internal Medicine, University of Iowa, Iowa City, IA
| | - Susan B Stempek
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Lahey Hospital and Medical Center, Burlington, MA
| | - Stacy A Trent
- Department of Emergency Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
- Department of Emergency Medicine, Denver Health Medical Center, Denver, CO
| | - Derek J Vonderhaar
- Department of Pulmonary and Critical Care Medicine, Ochsner Health System, New Orleans, LA
| | - Jason R West
- Department of Emergency Medicine, NYC Health + Hospitals | Lincoln, Bronx, NY
| | - Micah R Whitson
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL
| | - Kayla Williamson
- Department of Biostatistics & Informatics, Center for Innovative Design & Analysis, Colorado School of Public Health, Aurora, CO
| | - Matthew W Semler
- Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN
| | - Jonathan D Casey
- Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
| |
Collapse
|
28
|
Seitz KP, Spicer AB, Casey JD, Buell KG, Qian ET, Graham Linck EJ, Driver BE, Self WH, Ginde AA, Trent SA, Gandotra S, Smith LM, Page DB, Vonderhaar DJ, West JR, Joffe AM, Doerschug KC, Hughes CG, Whitson MR, Prekker ME, Rice TW, Sinha P, Semler MW, Churpek MM. Individualized Treatment Effects of Bougie versus Stylet for Tracheal Intubation in Critical Illness. Am J Respir Crit Care Med 2023; 207:1602-1611. [PMID: 36877594 PMCID: PMC10273111 DOI: 10.1164/rccm.202209-1799oc] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 03/06/2023] [Indexed: 03/07/2023] Open
Abstract
Rationale: A recent randomized trial found that using a bougie did not increase the incidence of successful intubation on first attempt in critically ill adults. The average effect of treatment in a trial population, however, may differ from effects for individuals. Objective: We hypothesized that application of a machine learning model to data from a clinical trial could estimate the effect of treatment (bougie vs. stylet) for individual patients based on their baseline characteristics ("individualized treatment effects"). Methods: This was a secondary analysis of the BOUGIE (Bougie or Stylet in Patients Undergoing Intubation Emergently) trial. A causal forest algorithm was used to model differences in outcome probabilities by randomized group assignment (bougie vs. stylet) for each patient in the first half of the trial (training cohort). This model was used to predict individualized treatment effects for each patient in the second half (validation cohort). Measurements and Main Results: Of 1,102 patients in the BOUGIE trial, 558 (50.6%) were the training cohort, and 544 (49.4%) were the validation cohort. In the validation cohort, individualized treatment effects predicted by the model significantly modified the effect of trial group assignment on the primary outcome (P value for interaction = 0.02; adjusted qini coefficient, 2.46). The most important model variables were difficult airway characteristics, body mass index, and Acute Physiology and Chronic Health Evaluation II score. Conclusions: In this hypothesis-generating secondary analysis of a randomized trial with no average treatment effect and no treatment effect in any prespecified subgroups, a causal forest machine learning algorithm identified patients who appeared to benefit from the use of a bougie over a stylet and from the use of a stylet over a bougie using complex interactions between baseline patient and operator characteristics.
Collapse
Affiliation(s)
- Kevin P. Seitz
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and
| | - Alexandra B. Spicer
- Division of Pulmonary and Critical Care, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin
| | - Jonathan D. Casey
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and
| | - Kevin G. Buell
- Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, Illinois
| | - Edward T. Qian
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and
| | - Emma J. Graham Linck
- Division of Pulmonary and Critical Care, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin
| | | | - Wesley H. Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- Vanderbilt Institute for Clinical and Translational Sciences, Nashville, Tennessee
| | - Adit A. Ginde
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado
| | - Stacy A. Trent
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado
- Department of Emergency Medicine, Denver Health Medical Center, Denver, Colorado
| | - Sheetal Gandotra
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, and
| | - Lane M. Smith
- Atrium Health Pulmonary Critical Care Medicine, Charlotte, North Carolina
| | - David B. Page
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, and
- Department of Emergency Medicine, University of Alabama Heersink School of Medicine, Birmingham, Alabama
| | - Derek J. Vonderhaar
- Department of Pulmonary and Critical Care Medicine, Ochsner Health System, New Orleans, Louisiana
- Section of Emergency Medicine, Louisiana State University School of Medicine, New Orleans, Louisiana
| | - Jason R. West
- Department of Emergency Medicine, Lincoln Medical Center, Bronx, New York City, New York
| | - Aaron M. Joffe
- Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington
| | - Kevin C. Doerschug
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa; and
| | - Christopher G. Hughes
- Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington
| | - Micah R. Whitson
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, and
- Department of Emergency Medicine, University of Alabama Heersink School of Medicine, Birmingham, Alabama
| | - Matthew E. Prekker
- Department of Emergency Medicine and
- Division of Pulmonary and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, Minnesota
| | - Todd W. Rice
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and
| | - Pratik Sinha
- Division of Clinical and Translational Research and
- Division of Critical Care, Department of Anesthesia, Washington University School of Medicine, Saint Louis, Missouri
| | - Matthew W. Semler
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and
| | - Matthew M. Churpek
- Division of Pulmonary and Critical Care, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin
| |
Collapse
|
29
|
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis 2023; 23:696-705. [PMID: 36780912 PMCID: PMC10014040 DOI: 10.1016/s1473-3099(23)00011-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 12/12/2022] [Accepted: 12/30/2022] [Indexed: 02/12/2023]
Abstract
BACKGROUND Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2, and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 among individuals at high risk infected with delta and early omicron variants. However, less is known about the effectiveness of nirmatrelvir-ritonavir during more recent BA.2, BA2.12.1, BA.4, and BA.5 omicron variant surges. We used our real-world data platform to evaluate the effect of nirmatrelvir-ritonavir treatment on 28-day hospitalisation, mortality, and emergency department visits among outpatients with early symptomatic COVID-19 during a SARS-CoV-2 omicron (BA.2, BA2.12.1, BA.4, and BA.5) predominant period in Colorado, USA. METHODS We did a propensity-matched, retrospective, observational cohort study of non-hospitalised adult patients infected with SARS-CoV-2 between March 26 and Aug 25, 2022, using records from a statewide health system in Colorado. We obtained data from the electronic health records of University of Colorado Health, the largest health system in Colorado, with 13 hospitals and 141 000 annual hospital admissions, and with numerous ambulatory sites and affiliated pharmacies around the state. Included patients had a positive SARS-CoV-2 test or nirmatrelvir-ritonavir medication order. Exclusion criteria were an order for or administration of other SARS-CoV-2 treatments within 10 days of a positive SARS-CoV-2 test, hospitalisation at the time of positive SARS-CoV-2 test, and positive SARS-CoV-2 test more than 10 days before a nirmatrelvir-ritonavir order. We propensity score matched patients treated with nirmatrelvir-ritonavir with untreated patients. The primary outcome was 28-day all-cause hospitalisation. FINDINGS Among 28 167 patients infected with SARS-CoV-2 between March 26 and Aug 25, 2022, 21 493 met the study inclusion criteria. 9881 patients received treatment with nirmatrelvir-ritonavir and 11 612 were untreated. Nirmatrelvir-ritonavir treatment was associated with reduced 28-day all-cause hospitalisation compared with no antiviral treatment (61 [0·9%] of 7168 patients vs 135 [1·4%] of 9361 patients, adjusted odds ratio (OR) 0·45 [95% CI 0·33-0·62]; p<0·0001). Nirmatrelvir-ritonavir treatment was also associated with reduced 28-day all-cause mortality (two [<0·1%] of 7168 patients vs 15 [0·2%] of 9361 patients; adjusted OR 0·15 [95% CI 0·03-0·50]; p=0·0010). Using subsequent emergency department visits as a surrogate for clinically significant relapse, we observed a decrease after nirmatrelvir-ritonavir treatment (283 [3·9%] of 7168 patients vs 437 [4·7%] of 9361 patients; adjusted OR 0·74 [95% CI 0·63-0·87]; p=0·0002). INTERPRETATION Real-world evidence reported during a BA.2, BA2.12.1, BA.4, and BA.5 omicron surge showed an association between nirmatrelvir-ritonavir treatment and reduced 28-day all-cause hospitalisation, all-cause mortality, and visits to the emergency department. With results that are among the first to suggest effectiveness of nirmatrelvir-ritonavir for non-hospitalised patients during an omicron period inclusive of BA.4 and BA.5 subvariants, these data support nirmatrelvir-ritonavir as an ongoing first-line treatment for adults acutely infected with SARS-CoV-2. FUNDING US National Institutes of Health.
Collapse
Affiliation(s)
- Neil R Aggarwal
- Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
| | - Kyle C Molina
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA; Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; Department of Pharmacy, University of Colorado Hospital, Aurora, CO, USA
| | - Laurel E Beaty
- Department of Biostatistics and Informatics, Colorado School of Public Health and Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Tellen D Bennett
- Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO, USA; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Nichole E Carlson
- Department of Biostatistics and Informatics, Colorado School of Public Health and Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - David A Mayer
- Department of Biostatistics and Informatics, Colorado School of Public Health and Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Jennifer L Peers
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Seth Russell
- Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO, USA; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Matthew K Wynia
- Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA; Department of Health Systems Management and Policy, Colorado School of Public Health and Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; University of Colorado Center for Bioethics and Humanities, Aurora, CO, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| |
Collapse
|
30
|
Mould-Millman NK, Dixon JM, Lategan HJ, Beaty B, Fosdick B, Fleischer C, de Vries S, Schauer LSG, Steyn E, Verster J, Hodsdon L, Mukonkole S, Doubell K, Stassen W, Keenan S, Cunningham C, Moore EE, Ginde AA, Bebarta CVS. Feasibility of Conducting a Military-Relevant Multi-Center Cohort Study to Assess Outcomes of Early Trauma Resuscitative Interventions in a Prolonged Care Civilian Setting. J Trauma Acute Care Surg 2023:01586154-990000000-00384. [PMID: 37212617 PMCID: PMC10389497 DOI: 10.1097/ta.0000000000004066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
BACKGROUND The Epidemiology and Outcomes of Prolonged Trauma Care (EpiC) study is a 4-year, prospective, observational, large-scale epidemiologic study in South Africa. EpiC will provide novel evidence on how early resuscitation impacts post-injury mortality and morbidity in patients experiencing prolonged care. A pilot study was performed to inform the main EpiC study. We assess outcomes and experiences from the pilot to evaluate overall feasibility of conducting the main EpiC study. METHODS The pilot was a prospective, multi-center, cohort study at 4 ambulance bases, 4 hospitals, and 2 mortuaries from 25-March to 27-August, 2021. Trauma patients 18 years or older were included. Data were manually collected via chart review and abstraction from clinical records at all research sites and inputted into REDCap. Feasibility metrics calculated were: screening efficiency; adequate enrollment; availability of key exposure and outcome data; and, availability of injury event date/time. RESULTS 2303 patients were screened. Of the 981 included, 70% were male and the median age was 31.4 years. 6% had 1 or more trauma relevant comorbidity. 55% arrived by ambulance. 40% had penetrating injuries. 53% were critically injured. 33% had one or more critical interventions performed. Mortality was 5%. Four out of the 8 feasibility metrics exceed the predetermined threshold: screening ratio, monthly enrollment, % with significant organ failure, and missing injury date/time for EMS patients. Two feasibility metrics were borderline: key exposure and primary outcome. Two feasibility metrics fall below the feasibility threshold, which necessitate changes to the main EpiC study: % with infections and missing injury date/time for walk-in patients. CONCLUSIONS The EpiC pilot study suggests that the main EpiC study is overall feasible. Improved data collection for infections and methods for missing data will be developed for the main study. LEVEL OF EVIDENCE Prognostic and Epidemiological level III. STUDY TYPE Epidemiological.
Collapse
|
31
|
Surie D, Bonnell LN, DeCuir J, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Busse LW, Prekker ME, Peltan ID, Brown SM, Hager DN, Ali H, Gong MN, Mohamed A, Khan A, Wilson JG, Qadir N, Chang SY, Ginde AA, Huynh D, Mohr NM, Mallow C, Martin ET, Lauring AS, Johnson NJ, Casey JD, Gibbs KW, Kwon JH, Baughman A, Chappell JD, Hart KW, Grijalva CG, Rhoads JP, Swan SA, Keipp Talbot H, Womack KN, Zhu Y, Tenforde MW, Adams K, Self WH, McMorrow ML. Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022. Vaccine 2023:S0264-410X(23)00567-4. [PMID: 37301704 DOI: 10.1016/j.vaccine.2023.05.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 05/09/2023] [Accepted: 05/10/2023] [Indexed: 06/12/2023]
Abstract
BACKGROUND Accurate determination of COVID-19 vaccination status is necessary to produce reliable COVID-19 vaccine effectiveness (VE) estimates. Data comparing differences in COVID-19 VE by vaccination sources (i.e., immunization information systems [IIS], electronic medical records [EMR], and self-report) are limited. We compared the number of mRNA COVID-19 vaccine doses identified by each of these sources to assess agreement as well as differences in VE estimates using vaccination data from each individual source and vaccination data adjudicated from all sources combined. METHODS Adults aged ≥18 years who were hospitalized with COVID-like illness at 21 hospitals in 18 U.S. states participating in the IVY Network during February 1-August 31, 2022, were enrolled. Numbers of COVID-19 vaccine doses identified by IIS, EMR, and self-report were compared in kappa agreement analyses. Effectiveness of mRNA COVID-19 vaccines against COVID-19-associated hospitalization was estimated using multivariable logistic regression models to compare the odds of COVID-19 vaccination between SARS-CoV-2-positive case-patients and SARS-CoV-2-negative control-patients. VE was estimated using each source of vaccination data separately and all sources combined. RESULTS A total of 4499 patients were included. Patients with ≥1 mRNA COVID-19 vaccine dose were identified most frequently by self-report (n = 3570, 79 %), followed by IIS (n = 3272, 73 %) and EMR (n = 3057, 68 %). Agreement was highest between IIS and self-report for 4 doses with a kappa of 0.77 (95 % CI = 0.73-0.81). VE point estimates of 3 doses against COVID-19 hospitalization were substantially lower when using vaccination data from EMR only (VE = 31 %, 95 % CI = 16 %-43 %) than when using all sources combined (VE = 53 %, 95 % CI = 41 %-62%). CONCLUSION Vaccination data from EMR only may substantially underestimate COVID-19 VE.
Collapse
Affiliation(s)
- Diya Surie
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
| | - Levi N Bonnell
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States; General Dynamics Information Technology, Falls Church, VA, United States
| | - Jennifer DeCuir
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Manjusha Gaglani
- Baylor Scott & White Health and Texas A&M University College of Medicine, Temple, TX, United States
| | - Tresa McNeal
- Baylor Scott & White Health and Texas A&M University College of Medicine, Temple, TX, United States
| | - Shekhar Ghamande
- Baylor Scott & White Health and Texas A&M University College of Medicine, Temple, TX, United States
| | - Jay S Steingrub
- Department of Medicine, Baystate Medical Center, Springfield, MA, United States
| | - Nathan I Shapiro
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States
| | - Laurence W Busse
- Department of Medicine, Emory University, Atlanta, GA, United States
| | - Matthew E Prekker
- Department of Emergency Medicine and Medicine, Hennepin County Medical Center, Minneapolis, MN, United States
| | - Ithan D Peltan
- Department of Medicine, Intermountain Medical Center, Murray, UT and University of Utah, Salt Lake City, UT, United States
| | - Samuel M Brown
- Department of Medicine, Intermountain Medical Center, Murray, UT and University of Utah, Salt Lake City, UT, United States
| | - David N Hager
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Harith Ali
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Michelle N Gong
- Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, NY, United States
| | - Amira Mohamed
- Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, NY, United States
| | - Akram Khan
- Department of Medicine, Oregon Health and Sciences University, Portland, OR, United States
| | - Jennifer G Wilson
- Department of Emergency Medicine, Stanford University School of Medicine, Stanford, CA, United States
| | - Nida Qadir
- Department of Medicine, University of California-Los Angeles, Los Angeles, CA, United States
| | - Steven Y Chang
- Department of Medicine, University of California-Los Angeles, Los Angeles, CA, United States
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States
| | - David Huynh
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States
| | - Nicholas M Mohr
- Department of Emergency Medicine, University of Iowa, Iowa City, IA, United States
| | | | - Emily T Martin
- School of Public Health, University of Michigan, Ann Arbor, MI, United States
| | - Adam S Lauring
- Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, MI, United States
| | - Nicholas J Johnson
- Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA, United States
| | - Jonathan D Casey
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Kevin W Gibbs
- Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States
| | - Jennie H Kwon
- Department of Medicine, Washington University, St. Louis, MO, United States
| | - Adrienne Baughman
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Kimberly W Hart
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Carlos G Grijalva
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Jillian P Rhoads
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Sydney A Swan
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - H Keipp Talbot
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Kelsey N Womack
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Yuwei Zhu
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Mark W Tenforde
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Katherine Adams
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, United States; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Meredith L McMorrow
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
| |
Collapse
|
32
|
Wynia MK, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele JD, Stocker HR, Wogu AF, Zane RD, Sokol RJ, Ginde AA. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest 2023; 163:1061-1070. [PMID: 36441040 PMCID: PMC9613796 DOI: 10.1016/j.chest.2022.10.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 10/22/2022] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND Neutralizing monoclonal antibodies (mAbs) were authorized for the treatment of COVID-19 outpatients based on clinical trials completed early in the pandemic, which were underpowered for mortality and subgroup analyses. Real-world data studies are promising for further assessing rapidly deployed therapeutics. RESEARCH QUESTION Did mAb treatment prevent progression to severe disease and death across pandemic phases and based on risk factors, including prior vaccination status? STUDY DESIGN AND METHODS This observational cohort study included nonhospitalized adult patients with SARS-CoV-2 infection from November 2020 to October 2021 using electronic health records from a statewide health system plus state-level vaccine and mortality data. Using propensity matching, we selected approximately 2.5 patients not receiving mAbs for each patient who received mAb treatment under emergency use authorization. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and hospitalization severity. RESULTS Of 36,077 patients with SARS-CoV-2 infection, 2,675 receiving mAbs were matched to 6,677 patients not receiving mAbs. Compared with mAb-untreated patients, mAb-treated patients had lower all-cause hospitalization (4.0% vs 7.7%; adjusted OR, 0.48; 95% CI, 0.38-0.60) and all-cause mortality (0.1% vs 0.9%; adjusted OR, 0.11; 95% CI, 0.03-0.29) to day 28; differences persisted to day 90. Among hospitalized patients, mAb-treated patients had shorter hospital length of stay (5.8 vs 8.5 days) and lower risk of mechanical ventilation (4.6% vs 16.6%). Results were similar for preventing hospitalizations during the Delta variant phase (adjusted OR, 0.35; 95% CI, 0.25-0.50) and across subgroups. Number-needed-to-treat (NNT) to prevent hospitalization was lower for subgroups with higher baseline risk of hospitalization; for example, multiple comorbidities (NNT = 17) and not fully vaccinated (NNT = 24) vs no comorbidities (NNT = 88) and fully vaccinated (NNT = 81). INTERPRETATION Real-world data revealed a strong association between receipt of mAbs and reduced hospitalization and deaths among COVID-19 outpatients across pandemic phases. Real-world data studies should be used to guide practice and policy decisions, including allocation of scarce resources.
Collapse
Affiliation(s)
- Matthew K Wynia
- Center for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus, Aurora, CO; Department of Health Systems Management and Policy, Colorado School of Public Health, Aurora, CO; Department of Medicine, University of Colorado School of Medicine, Aurora, CO
| | - Laurel E Beaty
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO
| | - Tellen D Bennett
- Colorado Clinical and Translational Sciences Institute, University of Colorado, Anschutz Medical Campus, Aurora, CO; Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO
| | - Nichole E Carlson
- Colorado Clinical and Translational Sciences Institute, University of Colorado, Anschutz Medical Campus, Aurora, CO; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO
| | - Christopher B Davis
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO
| | - Bethany M Kwan
- Colorado Clinical and Translational Sciences Institute, University of Colorado, Anschutz Medical Campus, Aurora, CO; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO; Department of Family Medicine, University of Colorado School of Medicine, Aurora, CO
| | - David A Mayer
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO
| | - Toan C Ong
- Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO
| | - Seth Russell
- Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO
| | | | - Heather R Stocker
- Department of Family Medicine, University of Colorado School of Medicine, Aurora, CO
| | - Adane F Wogu
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO
| | - Richard D Zane
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO
| | - Ronald J Sokol
- Colorado Clinical and Translational Sciences Institute, University of Colorado, Anschutz Medical Campus, Aurora, CO; Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO
| | - Adit A Ginde
- Colorado Clinical and Translational Sciences Institute, University of Colorado, Anschutz Medical Campus, Aurora, CO; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO.
| |
Collapse
|
33
|
DeCuir J, Surie D, Zhu Y, Gaglani M, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, McNeal T, Ghamande S, Gibbs KW, Files DC, Hager DN, Phan M, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Bender WS, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Exline MC, Lauring AS, Shapiro NI, Columbus C, Gottlieb R, Vaughn IA, Ramesh M, Lamerato LE, Safdar B, Halasa N, Chappell JD, Grijalva CG, Baughman A, Womack KN, Rhoads JP, Hart KW, Swan SA, Lewis N, McMorrow ML, Self WH. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:463-468. [PMID: 37104244 DOI: 10.15585/mmwr.mm7217a3] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths in the United States, with approximately 75% of deaths occurring among adults aged ≥65 years (1). Data on the durability of protection provided by monovalent mRNA COVID-19 vaccination against critical outcomes of COVID-19 are limited beyond the Omicron BA.1 lineage period (December 26, 2021-March 26, 2022). In this case-control analysis, the effectiveness of 2-4 monovalent mRNA COVID-19 vaccine doses was evaluated against COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death among immunocompetent adults aged ≥18 years during February 1, 2022-January 31, 2023. Vaccine effectiveness (VE) against IMV and in-hospital death was 62% among adults aged ≥18 years and 69% among those aged ≥65 years. When stratified by time since last dose, VE was 76% at 7-179 days, 54% at 180-364 days, and 56% at ≥365 days. Monovalent mRNA COVID-19 vaccination provided substantial, durable protection against IMV and in-hospital death among adults during the Omicron variant period. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical COVID-19-associated outcomes.
Collapse
|
34
|
Mould-Millman NK, Dixon J, Beaty BL, Suresh K, de Vries S, Bester B, Moreira F, Cunningham C, Moodley K, Cermak R, Schauer SG, Maddry JK, Bills CB, Havranek EP, Bebarta VS, Ginde AA. Improving prehospital traumatic shock care: implementation and clinical effectiveness of a pragmatic, quasi-experimental trial in a resource-constrained South African setting. BMJ Open 2023; 13:e060338. [PMID: 37185181 PMCID: PMC10151988 DOI: 10.1136/bmjopen-2021-060338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Accepted: 04/13/2023] [Indexed: 05/17/2023] Open
Abstract
OBJECTIVES This project seeks to improve providers' practices and patient outcomes from prehospital (ie, ambulance-based) trauma care in a middle-income country using a novel implementation strategy to introduce a bundled clinical intervention. DESIGN We conduct a two-arm, controlled, mixed-methods, hybrid type II study. SETTING This study was conducted in the Western Cape Government Emergency Medical Services (EMS) system of South Africa. INTERVENTIONS We pragmatically implemented a simplified prehospital bundle of trauma care (with five core elements) using a novel workplace-based, peer-to-peer, rapid training format. We assigned the intervention and control sites. OUTCOME MEASURES We assessed implementation effectiveness among EMS providers and stakeholders, using the RE-AIM framework. Clinical effectiveness was assessed at the patient level, using changes in Shock Index x Age (SIxAge). Indices and cut-offs were established a priori. We performed a difference-in-differences (D-I-D) analysis with a multivariable mixed effects model. RESULTS 198 of 240 (82.5%) EMS providers participated, 93 (47%) intervention and 105 (53%) control, with similar baseline characteristics. The overall implementation effectiveness was excellent (80.6%): reach was good (65%), effectiveness was excellent (87%), implementation fidelity was good (72%) and adoption was excellent (87%). Participants and stakeholders generally reported very high satisfaction with the implementation strategy citing that it was a strong operational fit and effective educational model for their organisation. A total of 770 patients were included: 329 (42.7%) interventions and 441 (57.3%) controls, with no baseline differences. Intervention arm patients had more improved SIxAge compared with control at 4 months, which was not statistically significant (-1.4 D-I-D; p=0.35). There was no significant difference in change of SIxAge over time between the groups for any of the other time intervals (p=0.99). CONCLUSIONS In this quasi-experimental trial of bundled care using the novel workplace rapid training approach, we found overall excellent implementation effectiveness but no overall statistically significant clinical effectiveness.
Collapse
Affiliation(s)
- Nee-Kofi Mould-Millman
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Julia Dixon
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Brenda L Beaty
- Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, USA
| | - Krithika Suresh
- Department of Biostatistics & Informatics, University of Colorado School of Public Health, Aurora, Colorado, USA
| | - Shaheem de Vries
- Emergency Medical Services, Western Cape Government Department of Health, City of Cape Town, South Africa
| | - Beatrix Bester
- Emergency Medical Services, Western Cape Government Department of Health, City of Cape Town, South Africa
| | - Fabio Moreira
- Emergency Medical Services, Western Cape Government Department of Health, City of Cape Town, South Africa
| | - Charmaine Cunningham
- Division of Emergency Medicine, University of Cape Town Faculty of Health Sciences, Belville, South Africa
| | - Kubendhren Moodley
- Emergency Medical Services, Western Cape Government Department of Health, City of Cape Town, South Africa
| | - Radomir Cermak
- Emergency Medical Services, Western Cape Government Department of Health, City of Cape Town, South Africa
| | - Steven G Schauer
- US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, USA
| | - Joseph K Maddry
- US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, USA
| | - Corey B Bills
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Edward P Havranek
- Department of Medicine, Denver Health Medical Center, Denver, Colorado, USA
| | - Vikhyat S Bebarta
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| |
Collapse
|
35
|
Brown SM, Katz MJ, Ginde AA, Juneja K, Ramchandani M, Schiffer JT, Vaca C, Gottlieb RL, Tian Y, Elboudwarej E, Hill JA, Gilson R, Rodriguez L, Hedskog C, Chen S, Montezuma-Rusca JM, Osinusi A, Paredes R. Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. Infect Dis Ther 2023; 12:1189-1203. [PMID: 37074613 PMCID: PMC10113728 DOI: 10.1007/s40121-023-00789-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 02/28/2023] [Indexed: 04/20/2023] Open
Abstract
INTRODUCTION In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results of assessment of heterogeneity of treatment effect (HTE) of early outpatient remdesivir, focusing on time from symptom onset and number of baseline risk factors (RFs). METHODS PINETREE was a double-blind, placebo-controlled trial of non-hospitalized patients with COVID-19 who were randomized within 7 days of symptom onset and had ≥ 1 RF for disease progression (age ≥ 60 years, obesity [body mass index ≥ 30], or certain coexisting medical conditions). Patients received remdesivir intravenously (200 mg on day 1 and 100 mg on days 2 and 3) or placebo. RESULTS In this subgroup analysis, HTE of remdesivir by time from symptom onset at treatment initiation and number of baseline RFs was not detected. Treatment with remdesivir reduced COVID-19-related hospitalizations independent of stratification by time from symptom onset to randomization. Of patients enrolled ≤ 5 days from symptom onset, 1/201 (0.5%) receiving remdesivir and 9/194 (4.6%) receiving placebo were hospitalized (hazard ratio [HR] 0.10; 95% confidence interval [CI] 0.01-0.82). Of those enrolled at > 5 days from symptom onset, 1/78 (1.3%) receiving remdesivir and 6/89 (6.7%) receiving placebo were hospitalized (HR 0.19; 95% CI 0.02-1.61). Remdesivir was also effective in reducing COVID-19-related hospitalizations when stratified by number of baseline RFs for severe disease. Of patients with ≤ 2 RFs, 0/159 (0.0%) receiving remdesivir and 4/164 (2.4%) receiving placebo were hospitalized; of those with ≥ 3 RFs, 2/120 (1.7%) receiving remdesivir and 11/119 (9.2%) receiving placebo were hospitalized (HR 0.16; 95% CI 0.04-0.73). CONCLUSIONS In the outpatient setting, benefit of remdesivir initiated within 7 days of symptoms appeared to be consistent across patients with RFs. Therefore, it may be reasonable to broadly treat patients with remdesivir regardless of comorbidities. TRIAL REGISTRATION ClinicalTrials.gov number NCT04501952.
Collapse
Affiliation(s)
- Samuel M Brown
- Intermountain Healthcare and the University of Utah School of Medicine, Murray, UT, USA
| | - Morgan J Katz
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Adit A Ginde
- University of Colorado School of Medicine, Aurora, CO, USA
| | | | | | - Joshua T Schiffer
- Fred Hutchinson Cancer Center and the University of Washington School of Medicine, Seattle, WA, USA
| | - Carlos Vaca
- The Nuren Medical and Research Center, Miami, FL, USA
| | - Robert L Gottlieb
- Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX, USA
| | - Yuan Tian
- Gilead Sciences, Foster City, CA, USA
| | | | - Joshua A Hill
- Fred Hutchinson Cancer Center and the University of Washington School of Medicine, Seattle, WA, USA
| | | | | | | | | | | | | | - Roger Paredes
- Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol and irsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, 08916, Barcelona, Catalonia, Spain.
| |
Collapse
|
36
|
Molina KC, Kennerley V, Beaty LE, Bennett TD, Carlson NE, MayerIJ DA, Peers JL, Russell S, Wynia MK, Aggarwal NR, Ginde AA. Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5. Int J Infect Dis 2023; 132:34-39. [PMID: 37072054 PMCID: PMC10106116 DOI: 10.1016/j.ijid.2023.04.396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 04/05/2023] [Accepted: 04/11/2023] [Indexed: 04/20/2023] Open
Abstract
OBJECTIVES Bebtelovimab is an anti-SARS-CoV-2 monoclonal antibody active against Omicron lineage variants authorized to treat high-risk outpatients with COVID-19. We sought to determine the real-world effectiveness of bebtelovimab during Omicron phases BA.2/BA2.12.1/BA4/BA5. METHODS We conducted a retrospective cohort study of adults with SARS-CoV-2 infection between April 6 to October 11, 2022, using health records linked to vaccine and mortality data. We used propensity scores to match of bebtelovimab-treated with untreated outpatients. The primary outcome was 28-day all-cause hospitalization. Secondary outcomes were 28-day COVID-19-related hospitalization, 28-day all-cause mortality, 28-day ED visits, maximum respiratory support level, ICU admission, and in-hospital mortality among hospitalized patients. We used logistic regression to determine bebtelovimab treatment effectiveness. RESULTS Among 22,720 patients with SARS-COV-2 infection, 3,739 bebtelovimab-treated patients were matched to 5,423 untreated patients. Compared to no treatment, bebtelovimab was associated with lower odds of 28-day all-cause hospitalization (1.3% vs. 2.1%, adjusted odds ratio (aOR): 0.53 [95%CI 0.37-0.74], p <0.001) as well as COVID-19 related hospitalization (1.0% vs. 2.0%, aOR:0.44 [95%CI 0.30-0.64], p <0.001). Bebtelovimab appeared more beneficial in lowering the odds of hospitalization among patients with two or more comorbidities (interaction p=0.03). CONCLUSIONS During the Omicron BA.2/BA.2.12.1/BA.4/BA.5 variant phase, bebtelovimab was associated with lower hospitalization.
Collapse
Affiliation(s)
- Kyle C Molina
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA; Department of Pharmacy, Scripps Health, La Jolla, CA, 92037, USA.
| | - Victoria Kennerley
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Laurel E Beaty
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Tellen D Bennett
- Departments of Biomedical Informatics and Pediatrics, University of Colorado School of Medicine; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
| | - Nichole E Carlson
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - David A MayerIJ
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 80045, USA
| | - Jennifer L Peers
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| | - Seth Russell
- Departments of Biomedical Informatics, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
| | - Matthew K Wynia
- Department of Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA; University of Colorado Center for Bioethics and Humanities; Department of Health Systems Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA
| | - Neil R Aggarwal
- Department of Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| |
Collapse
|
37
|
Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine N, Tiffany B, Douglas IS, Levitt J, Busse LW, Ginde AA, Brown SM, Hager DN, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall AJ, DeClercq J, Lavieri R, Joly MM, Orr M, Pulley J, Rice TW, Schildcrout JS, Semler MW, Wang L, Bernard GR, Collins SP. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA 2023; 329:1170-1182. [PMID: 37039791 PMCID: PMC10091180 DOI: 10.1001/jama.2023.3546] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 02/24/2023] [Indexed: 04/12/2023]
Abstract
Importance Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an important contributor to COVID-19 pathophysiology. Objective To evaluate the efficacy and safety of RAS modulation using 2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand), that are hypothesized to potentiate the action of angiotensin (1-7) and mitigate the action of the angiotensin II. Design, Setting, and Participants Two randomized clinical trials including adults hospitalized with acute COVID-19 and new-onset hypoxemia were conducted at 35 sites in the US between July 22, 2021, and April 20, 2022; last follow-up visit: July 26, 2022. Interventions A 0.5-mg/kg intravenous infusion of TXA-127 once daily for 5 days or placebo. A 12-mg/h continuous intravenous infusion of TRV-027 for 5 days or placebo. Main Outcomes and Measures The primary outcome was oxygen-free days, an ordinal outcome that classifies a patient's status at day 28 based on mortality and duration of supplemental oxygen use; an adjusted odds ratio (OR) greater than 1.0 indicated superiority of the RAS agent vs placebo. A key secondary outcome was 28-day all-cause mortality. Safety outcomes included allergic reaction, new kidney replacement therapy, and hypotension. Results Both trials met prespecified early stopping criteria for a low probability of efficacy. Of 343 patients in the TXA-127 trial (226 [65.9%] aged 31-64 years, 200 [58.3%] men, 225 [65.6%] White, and 274 [79.9%] not Hispanic), 170 received TXA-127 and 173 received placebo. Of 290 patients in the TRV-027 trial (199 [68.6%] aged 31-64 years, 168 [57.9%] men, 195 [67.2%] White, and 225 [77.6%] not Hispanic), 145 received TRV-027 and 145 received placebo. Compared with placebo, both TXA-127 (unadjusted mean difference, -2.3 [95% CrI, -4.8 to 0.2]; adjusted OR, 0.88 [95% CrI, 0.59 to 1.30]) and TRV-027 (unadjusted mean difference, -2.4 [95% CrI, -5.1 to 0.3]; adjusted OR, 0.74 [95% CrI, 0.48 to 1.13]) resulted in no difference in oxygen-free days. In the TXA-127 trial, 28-day all-cause mortality occurred in 22 of 163 patients (13.5%) in the TXA-127 group vs 22 of 166 patients (13.3%) in the placebo group (adjusted OR, 0.83 [95% CrI, 0.41 to 1.66]). In the TRV-027 trial, 28-day all-cause mortality occurred in 29 of 141 patients (20.6%) in the TRV-027 group vs 18 of 140 patients (12.9%) in the placebo group (adjusted OR, 1.52 [95% CrI, 0.75 to 3.08]). The frequency of the safety outcomes was similar with either TXA-127 or TRV-027 vs placebo. Conclusions and Relevance In adults with severe COVID-19, RAS modulation (TXA-127 or TRV-027) did not improve oxygen-free days vs placebo. These results do not support the hypotheses that pharmacological interventions that selectively block the angiotensin II type 1 receptor or increase angiotensin (1-7) improve outcomes for patients with severe COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04924660.
Collapse
Affiliation(s)
- Wesley H. Self
- Vanderbilt Institute for Clinical and Translational Research, Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Matthew S. Shotwell
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Kevin W. Gibbs
- Department of Medicine, Wake Forest University, Winston-Salem, North Carolina
| | - Marjolein de Wit
- Department of Medicine, Virginia Commonwealth University, Richmond
| | - D. Clark Files
- Department of Medicine, Wake Forest University, Winston-Salem, North Carolina
| | - Michelle Harkins
- Department of Internal Medicine, University of New Mexico, Albuquerque
| | | | - Lisa H. Merck
- Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond
| | - Ari Moskowitz
- Department of Medicine, Montefiore Medical Center, Bronx, New York
| | | | - Aaron Barksdale
- Department of Emergency Medicine, University of Nebraska Medical Center, Omaha
| | - Basmah Safdar
- Department of Emergency Medicine, Yale University, New Haven, Connecticut
| | - Ali Javaheri
- Department of Medicine, Washington University, St Louis, Missouri
| | | | - Harry Schrager
- Department of Medicine, Tufts School of Medicine, Newton-Wellesley Hospital, Newton, Massachusetts
| | - Nicole Iovine
- Department of Medicine, University of Florida, Gainesville
| | | | - Ivor S. Douglas
- Department of Medicine, Denver Health Medical Center, Denver, Colorado
| | - Joseph Levitt
- Department of Medicine, Stanford University, Stanford, California
| | | | - Adit A. Ginde
- Department of Emergency Medicine, School of Medicine, University of Colorado, Aurora
| | - Samuel M. Brown
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Murray, Utah
| | - David N. Hager
- Department of Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Katherine Boyle
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - Abhijit Duggal
- Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
| | - Akram Khan
- Department of Medicine, Oregon Health & Science University, Portland
| | - Michael Lanspa
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Murray, Utah
| | - Peter Chen
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
| | - Michael Puskarich
- Department of Emergency Medicine, University of Minnesota, Minneapolis
| | - Derek Vonderhaar
- Department of Medicine, Ochsner Medical Center, New Orleans, Louisiana
| | | | - Nina Gentile
- Department of Emergency Medicine, Temple University, Philadelphia, Pennsylvania
| | - Yves Rosenberg
- National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | - James Troendle
- National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | - Amanda J. Bistran-Hall
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Josh DeClercq
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Robert Lavieri
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Meghan Morrison Joly
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Michael Orr
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Jill Pulley
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Todd W. Rice
- Vanderbilt Institute for Clinical and Translational Research, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | | | - Matthew W. Semler
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Li Wang
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Gordon R. Bernard
- Vanderbilt Institute for Clinical and Translational Research, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Sean P. Collins
- Vanderbilt Institute for Clinical and Translational Research, Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Healthcare System, Nashville
| |
Collapse
|
38
|
Gibbs KW, Ginde AA, Prekker ME, Seitz KP, Stempek SB, Taylor C, Gandotra S, White H, Resnick-Ault D, Khan A, Mohmed A, Brainard JC, Fein DG, Aggarwal NR, Whitson MR, Halliday SJ, Gaillard JP, Blinder V, Driver BE, Palakshappa JA, Lloyd BD, Wozniak JM, Exline MC, Russell DW, Ghamande S, Withers C, Hubel KA, Moskowitz A, Bastman J, Andrea L, Sottile PD, Page DB, Long MT, Goranson JK, Malhotra R, Long BJ, Schauer SG, Connor A, Anderson E, Maestas K, Rhoads JP, Womack K, Imhoff B, Janz DR, Trent SA, Self WH, Rice TW, Semler MW, Casey JD. Protocol and statistical analysis plan for the PREOXI trial of preoxygenation with noninvasive ventilation vs oxygen mask. medRxiv 2023:2023.03.23.23287539. [PMID: 36993496 PMCID: PMC10055579 DOI: 10.1101/2023.03.23.23287539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 04/23/2023]
Abstract
Background Hypoxemia is a common and life-threatening complication during emergency tracheal intubation of critically ill adults. The administration of supplemental oxygen prior to the procedure ("preoxygenation") decreases the risk of hypoxemia during intubation. Research Question Whether preoxygenation with noninvasive ventilation prevents hypoxemia during tracheal intubation of critically ill adults, compared to preoxygenation with oxygen mask, remains uncertain. Study Design and Methods The PRagmatic trial Examining OXygenation prior to Intubation (PREOXI) is a prospective, multicenter, non-blinded randomized comparative effectiveness trial being conducted in 7 emergency departments and 17 intensive care units across the United States. The trial compares preoxygenation with noninvasive ventilation versus oxygen mask among 1300 critically ill adults undergoing emergency tracheal intubation. Eligible patients are randomized in a 1:1 ratio to receive either noninvasive ventilation or an oxygen mask prior to induction. The primary outcome is the incidence of hypoxemia, defined as a peripheral oxygen saturation <85% between induction and 2 minutes after intubation. The secondary outcome is the lowest oxygen saturation between induction and 2 minutes after intubation. Enrollment began on 10 March 2022 and is expected to conclude in 2023. Interpretation The PREOXI trial will provide important data on the effectiveness of noninvasive ventilation and oxygen mask preoxygenation for the prevention of hypoxemia during emergency tracheal intubation. Specifying the protocol and statistical analysis plan prior to the conclusion of enrollment increases the rigor, reproducibility, and interpretability of the trial. Clinical trial registration number NCT05267652.
Collapse
Affiliation(s)
- Kevin W. Gibbs
- Section on Pulmonary, Critical Care, Allergy, and immunology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Adit A. Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA
| | - Matthew E. Prekker
- Division of Pulmonary and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, MN, USA
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA
| | - Kevin P. Seitz
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Susan B. Stempek
- Department of Medicine, Division of Pulmonary & Critical Care Medicine, Lahey Hospital & Medical Center, Burlington, MA, USA
| | - Caleb Taylor
- Pulmonary, Critical Care and Sleep Medicine, The Ohio State University, Columbus, OH, USA
| | - Sheetal Gandotra
- Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham, Birmingham, AL, USA
| | - Heath White
- Department of Medicine, Division of pulmonary & Critical Care Medicine, Baylor Scott & White Medical Center, Temple, TX, USA
| | - Daniel Resnick-Ault
- Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA
| | - Akram Khan
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Amira Mohmed
- Division of Critical Care Medicine Montefiore Medical Center Bronx, NY, USA
| | - Jason C. Brainard
- Department of Anesthesiology University of Colorado School of Medicine Aurora, CO, USA
| | - Daniel G. Fein
- Division of Pulmonary Medicine Montefiore Medical Center Bronx, NY, USA
| | - Neil R. Aggarwal
- Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Micah R. Whitson
- Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham, Birmingham, AL, USA
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Stephen J. Halliday
- Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wi, USA
| | - John P. Gaillard
- Department of Anesthesiology, Section on Critical Care ,Wake Forest School of Medicine, Winston-Salem, NC, USA
- Department of Emergency Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Veronika Blinder
- Division of Critical Care Medicine Montefiore Medical Center Bronx, NY, USA
| | - Brian E. Driver
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA
| | - Jessica A. Palakshappa
- Section on Pulmonary, Critical Care, Allergy, and immunology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Bradley D. Lloyd
- Vanderbilt Institute for Clinical and Translational Research, and Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Joanne M. Wozniak
- Department of Medicine, Division of Pulmonary & Critical Care Medicine, Lahey Hospital & Medical Center, Burlington, MA, USA
| | - Matthew C. Exline
- Pulmonary, Critical Care and Sleep Medicine, The Ohio State University, Columbus, OH, USA
| | - Derek W. Russell
- Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham, Birmingham, AL, USA
- Pulmonary Section, Birmingham VA medical Center, Birmingham, AL, USA
| | - Shekhar Ghamande
- Department of Medicine, Division of pulmonary & Critical Care Medicine, Baylor Scott & White Medical Center, Temple, TX, USA
| | - Cori Withers
- Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA
| | - Kinsley A. Hubel
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Ari Moskowitz
- Division of Critical Care Medicine Montefiore Medical Center Bronx, NY, USA
| | - Jill Bastman
- Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA
| | - Luke Andrea
- Division of Critical Care Medicine Montefiore Medical Center Bronx, NY, USA
| | - Peter D. Sottile
- Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - David B. Page
- Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham, Birmingham, AL, USA
| | - Micah T. Long
- Department of Anesthesiology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA
| | - Jordan Kugler Goranson
- Department of Emergency Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Rishi Malhotra
- Division of Critical Care Medicine Montefiore Medical Center Bronx, NY, USA
| | - Brit J. Long
- 59 Medical Wing, United States Air Force, Fort Sam Houston, San Antonio, TX, USA
| | - Steven G. Schauer
- United States Army Institute of Surgical Research, Joint Base San Antonio-Fort Sam Houston, San Antoni, TX, USA
| | - Andrew Connor
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Erin Anderson
- Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA
| | - Kristin Maestas
- Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA
| | - Jillian P. Rhoads
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Kelsey Womack
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Brant Imhoff
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - David R. Janz
- University Medical Center New Orleans and the Department of Medicine, Section of Pulmonary/Critical Care Medicine and Allergy/Immunology, Louisiana State University School of Medicine, New Orleans, LA, USA
| | - Stacy A. Trent
- Department of Emergency Medicine, University of Colorado School of Medicine Aurora, CO, USA
- Department of Emergency Medicine, Denver Health Medical Center, Denver, CO, USA
| | - Wesley H. Self
- Vanderbilt Institute for Clinical and Translational Research, and Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Todd W. Rice
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Matthew W. Semler
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Jonathan D. Casey
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| |
Collapse
|
39
|
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Slandzicki AJ, Lim SC, Cohen J, Kavtaradze D, Amon AP, Gabriel A, Gentile N, Felker GM, Jayaweera D, McCarthy MW, Sulkowski M, Rothman RL, Wilson S, DeLong A, Remaly A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Thicklin F, Hanna GJ, Ginde AA, Castro M, McTigue K, Shenkman E, Hernandez AF. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA 2023; 329:888-897. [PMID: 36807465 PMCID: PMC9941969 DOI: 10.1001/jama.2023.1650] [Citation(s) in RCA: 25] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Accepted: 02/01/2023] [Indexed: 02/22/2023]
Abstract
Importance It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19. Objective To evaluate the effectiveness of ivermectin at a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo, for the treatment of early mild to moderate COVID-19. Design, Setting, and Participants The ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6) platform randomized clinical trial was designed to evaluate repurposed therapies among outpatients with mild to moderate COVID-19. A total of 1206 participants older than 30 years with confirmed COVID-19 experiencing at least 2 symptoms of acute infection for less than or equal to 7 days were enrolled at 93 sites in the US from February 16, 2022, through July 22, 2022, with follow-up data through November 10, 2022. Interventions Participants were randomly assigned to receive ivermectin, with a maximum targeted dose of 600 μg/kg (n = 602) daily, or placebo (n = 604) for 6 days. Main Outcomes and Measures The primary outcome was time to sustained recovery, defined as at least 3 consecutive days without symptoms. The 7 secondary outcomes included a composite of hospitalization, death, or urgent/emergent care utilization by day 28. Results Among 1206 randomized participants who received study medication or placebo, the median (IQR) age was 48 (38-58) years, 713 (59.1%) were women, and 1008 (83.5%) reported receiving at least 2 SARS-CoV-2 vaccine doses. The median (IQR) time to sustained recovery was 11 (11-12) days in the ivermectin group and 11 (11-12) days in the placebo group. The hazard ratio (posterior probability of benefit) for improvement in time to recovery was 1.02 (95% credible interval, 0.92-1.13; P = .68). Among those receiving ivermectin, 34 (5.7%) were hospitalized, died, or had urgent or emergency care visits compared with 36 (6.0%) receiving placebo (hazard ratio, 1.0 [95% credible interval, 0.6-1.5]; P = .53). In the ivermectin group, 1 participant died and 4 were hospitalized (0.8%); 2 participants (0.3%) were hospitalized in the placebo group and there were no deaths. Adverse events were uncommon in both groups. Conclusions and Relevance Among outpatients with mild to moderate COVID-19, treatment with ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo did not improve time to sustained recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04885530.
Collapse
Affiliation(s)
- Susanna Naggie
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
| | - David R. Boulware
- Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis
| | | | | | | | - Stephen C. Lim
- University Medical Center New Orleans, Louisiana State University Health Sciences Center, New Orleans
| | - Jonathan Cohen
- Jadestone Clinical Research, LLC, Silver Spring, Maryland
| | | | - Arch P. Amon
- Lakeland Regional Medical Center, Lakeland, Florida
| | - Ahab Gabriel
- Focus Clinical Research Solutions, Charlotte, North Carolina
| | - Nina Gentile
- Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - G. Michael Felker
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
| | - Dushyantha Jayaweera
- Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida
| | | | - Mark Sulkowski
- Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland
| | | | - Sybil Wilson
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Allison DeLong
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - April Remaly
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Rhonda Wilder
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Sean Collins
- Vanderbilt University Medical Center, Nashville, Tennessee
- Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Nashville
| | - Sarah E. Dunsmore
- National Center for Advancing Translational Sciences, Bethesda, Maryland
| | - Stacey J. Adam
- Foundation for the National Institutes of Health, Bethesda, Maryland
| | | | - George J. Hanna
- Biomedical Advanced Research and Development Authority, Washington, DC
| | | | - Mario Castro
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Missouri-Kansas City School of Medicine, Kansas City
| | - Kathleen McTigue
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Elizabeth Shenkman
- Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville
| | - Adrian F. Hernandez
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
| |
Collapse
|
40
|
Tenforde MW, Patel MM, Lewis NM, Adams K, Gaglani M, Steingrub JS, Shapiro NI, Duggal A, Prekker ME, Peltan ID, Hager DN, Gong MN, Exline MC, Ginde AA, Mohr NM, Mallow C, Martin ET, Talbot HK, Gibbs KW, Kwon JH, Chappell JD, Halasa N, Lauring AS, Lindsell CJ, Swan SA, Hart KW, Womack KN, Baughman A, Grijalva CG, Self WH. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis 2023; 76:1030-1037. [PMID: 36327388 PMCID: PMC10226741 DOI: 10.1093/cid/ciac869] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 10/25/2022] [Accepted: 10/28/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic was associated with historically low influenza circulation during the 2020-2021 season, followed by an increase in influenza circulation during the 2021-2022 US season. The 2a.2 subgroup of the influenza A(H3N2) 3C.2a1b subclade that predominated was antigenically different from the vaccine strain. METHODS To understand the effectiveness of the 2021-2022 vaccine against hospitalized influenza illness, a multistate sentinel surveillance network enrolled adults aged ≥18 years hospitalized with acute respiratory illness and tested for influenza by a molecular assay. Using the test-negative design, vaccine effectiveness (VE) was measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2-negative controls, adjusting for confounders. A separate analysis was performed to illustrate bias introduced by including SARS-CoV-2-positive controls. RESULTS A total of 2334 patients, including 295 influenza cases (47% vaccinated), 1175 influenza- and SARS-CoV-2-negative controls (53% vaccinated), and 864 influenza-negative and SARS-CoV-2-positive controls (49% vaccinated), were analyzed. Influenza VE was 26% (95% CI: -14% to 52%) among adults aged 18-64 years, -3% (-54% to 31%) among adults aged ≥65 years, and 50% (15-71%) among adults aged 18-64 years without immunocompromising conditions. Estimated VE decreased with inclusion of SARS-CoV-2-positive controls. CONCLUSIONS During a season where influenza A(H3N2) was antigenically different from the vaccine virus, vaccination was associated with a reduced risk of influenza hospitalization in younger immunocompetent adults. However, vaccination did not provide protection in adults ≥65 years of age. Improvements in vaccines, antivirals, and prevention strategies are warranted.
Collapse
Affiliation(s)
- Mark W Tenforde
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Manish M Patel
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Nathaniel M Lewis
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Katherine Adams
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Manjusha Gaglani
- Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Jay S Steingrub
- Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA
| | - Nathan I Shapiro
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Abhijit Duggal
- Department of Medicine, Cleveland Clinic, Cleveland, Ohio, USA
| | - Matthew E Prekker
- Departments of Emergency Medicine and Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
| | - Ithan D Peltan
- Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City, Utah, USA
| | - David N Hager
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Michelle N Gong
- Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Matthew C Exline
- Department of Medicine, The Ohio State University, Columbus, Ohio, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Nicholas M Mohr
- Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA
| | | | - Emily T Martin
- School of Public Health, University of Michigan, Ann Arbor, Michigan, USA
| | - H Keipp Talbot
- Departments of Medicine and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kevin W Gibbs
- Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Jennie H Kwon
- Department of Medicine, Washington University, St Louis, Missouri, USA
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Natasha Halasa
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adam S Lauring
- Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
| | - Christopher J Lindsell
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Sydney A Swan
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kimberly W Hart
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kelsey N Womack
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adrienne Baughman
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Carlos G Grijalva
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Wesley H Self
- Vanderbilt Institute for Clinical and Translational Research and Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | |
Collapse
|
41
|
Molina KC, Ginde AA. Real-world use of nirmatrelvir-ritonavir: who benefits? Lancet Infect Dis 2023:S1473-3099(23)00180-9. [PMID: 36933566 PMCID: PMC10017109 DOI: 10.1016/s1473-3099(23)00180-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 03/03/2023] [Indexed: 03/17/2023]
Affiliation(s)
- Kyle C Molina
- Department of Emergency Medicine, Colorado University School of Medicine, Aurora, CO, USA; Scripps Health, La Jolla, CA, USA.
| | | |
Collapse
|
42
|
Abbate LM, Ollerenshaw LV, Kottmeyer BM, McQuown CM, Ragsdale LC, Richardson VL, Ho PM, Ginde AA, O'Malley SM. Integrating Physical Therapy into an Emergency Department: A Clinical Pilot Program. Acad Emerg Med 2023; 30:424-427. [PMID: 36912801 DOI: 10.1111/acem.14707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Revised: 02/21/2023] [Accepted: 02/21/2023] [Indexed: 03/14/2023]
Affiliation(s)
- Lauren M Abbate
- Eastern Colorado Geriatric Research Education and Clinical Center, Aurora, CO.,Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO
| | | | - Benjamin M Kottmeyer
- Physical Medicine and Rehabilitation, Rocky Mountain Regional VA Medical Center, Aurora, CO
| | - Colleen M McQuown
- Geriatric Research, Education and Clinic Center, Louis Stokes Cleveland VA Medical Center, Cleveland, OH
| | | | | | - P Michael Ho
- VA Denver-Seattle Center of Innovation (COIN) for Veteran-Centered & Value-Driven Care, Aurora, CO
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO
| | - Shane M O'Malley
- Physical Medicine and Rehabilitation, Rocky Mountain Regional VA Medical Center, Aurora, CO
| |
Collapse
|
43
|
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. Int J Infect Dis 2023; 128:310-317. [PMID: 36229005 PMCID: PMC9549713 DOI: 10.1016/j.ijid.2022.10.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 09/28/2022] [Accepted: 10/03/2022] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVES Sotrovimab effectively prevented progression to severe disease and mortality following infection with pre-Omicron SARS-CoV-2 variants. We sought to determine whether sotrovimab is similarly effective against SARS-CoV-2 Omicron variant infection. METHODS Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from December 26, 2021, to March 10, 2022, using electronic health records from a statewide health system. We propensity-matched patients not receiving authorized treatment for each patient treated with sotrovimab. The primary outcome was 28-day hospitalization; secondary outcomes included mortality. We also propensity-matched sotrovimab-treated patients from the Omicron and Delta phases. Logistic regression was used to determine sotrovimab effectiveness during Omicron and between variant phases. RESULTS Of 30,247 SARS-CoV-2 Omicron variant infected outpatients, we matched 1542 receiving sotrovimab to 3663 not receiving treatment. Sotrovimab treatment was not associated with reduced odds of 28-day hospitalization (2.5% vs 3.2%; adjusted odds ratio [OR] 0.82, 95% CI 0.55, 1.19) or mortality (0.1% vs 0.2%; adjusted OR 0.62, 95% CI 0.07, 2.78). Between phases, the observed treatment OR was higher during Omicron than during Delta (OR 0.85 vs 0.39, respectively; interaction P-value = 0.053). CONCLUSION Real-world evidence demonstrated that sotrovimab was not associated with reduced 28-day hospitalization or mortality among COVID-19 outpatients during the Omicron BA.1 phase.
Collapse
Affiliation(s)
- Neil R Aggarwal
- Department of Medicine, University of Colorado School of Medicine, Aurora, USA.
| | - Laurel E Beaty
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, USA
| | - Tellen D Bennett
- Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, USA; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, USA
| | - Nichole E Carlson
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, USA; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, USA
| | - David A Mayer
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, USA
| | - Kyle C Molina
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, USA
| | - Jennifer L Peers
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, USA
| | - Seth Russell
- Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, USA
| | - Matthew K Wynia
- Department of Medicine, University of Colorado School of Medicine, Aurora, USA; Center for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus, Aurora, USA; Department of Health Systems Management and Policy, Colorado School of Public Health, Aurora, USA
| | - Adit A Ginde
- Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, USA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, USA
| |
Collapse
|
44
|
Kaizer AM, Shapiro NI, Wild J, Brown SM, Cwik BJ, Hart KW, Jones AE, Pulia MS, Self WH, Smith C, Smith SA, Ng PC, Thompson BT, Rice TW, Lindsell CJ, Ginde AA. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. Int J Infect Dis 2023; 128:223-229. [PMID: 36581186 PMCID: PMC9792182 DOI: 10.1016/j.ijid.2022.12.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 12/19/2022] [Accepted: 12/21/2022] [Indexed: 12/28/2022] Open
Abstract
OBJECTIVES Effective and widely available therapies are still needed for outpatients with COVID-19. We aimed to evaluate the efficacy and safety of lopinavir/ritonavir (LPV/r) for early treatment of non-hospitalized individuals diagnosed with COVID-19. METHODS This randomized, placebo (Plb)-controlled, double-blind, multi-site decentralized clinical trial enrolled non-hospitalized adults with confirmed SARS-CoV-2 infection and six or fewer days of acute respiratory infection symptoms who were randomized to either twice-daily oral LPV/r (400 mg/100 mg) or Plb for 14 days. Daily surveys on study days 1 through 16 and again on study day 28 evaluated symptoms, daily activities, and hospitalization status. The primary outcome was longitudinal change in an ordinal scale based on a combination of symptoms, activity, and hospitalization status through day 15 and was analyzed by use of a Bayesian longitudinal proportional odds logistic regression model for estimating the probability of a superior recovery for LPV/r over Plb (odds ratio >1). RESULTS Between June 2020 and December 2021, 448 participants were randomized to receive either LPV/r (n = 216) or Plb (n = 221). The mean symptom duration before randomization was 4.3 days (SD 1.3). There were no differences between treatment groups through the first 15 days for the ordinal primary outcome (odds ratio 0.96; 95% credible interval: 0.66 to 1.41). There were 3.2% (n = 7) of LPV/r and 2.7% (n = 6) of Plb participants hospitalized by day 28. Serious adverse events did not differ between groups. CONCLUSION LPV/r did not significantly improve symptom resolution or reduce hospitalization in non-hospitalized participants with COVID-19. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04372628.
Collapse
Affiliation(s)
- Alexander M Kaizer
- Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Nathan I Shapiro
- Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Jessica Wild
- Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Samuel M Brown
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Murray, Utah, USA
| | - B Jessica Cwik
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Kimberly W Hart
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Alan E Jones
- Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, Missouri, USA
| | - Michael S Pulia
- BerbeeWalsh Department of Emergency Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Wesley H Self
- Vanderbilt Institute for Clinical and Translational Research and Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Clay Smith
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Stephanie A Smith
- Vanderbilt Coordinating Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Patrick C Ng
- San Antonio Military Medical Center, En route Care Research Center, 59th Medical Wing/Office of Science and Technology, US Air Force 59th Medical Wing, Joint Base San Antonio-Lackland, Texas, USA
| | - B Taylor Thompson
- Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Todd W Rice
- Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Christopher J Lindsell
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
| |
Collapse
|
45
|
Shapiro NI, Douglas IS, Brower RG, Brown SM, Exline MC, Ginde AA, Gong MN, Grissom CK, Hayden D, Hough CL, Huang W, Iwashyna TJ, Jones AE, Khan A, Lai P, Liu KD, Miller CD, Oldmixon K, Park PK, Rice TW, Ringwood N, Semler MW, Steingrub JS, Talmor D, Thompson BT, Yealy DM, Self WH. Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. N Engl J Med 2023; 388:499-510. [PMID: 36688507 PMCID: PMC10685906 DOI: 10.1056/nejmoa2212663] [Citation(s) in RCA: 74] [Impact Index Per Article: 74.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND Intravenous fluids and vasopressor agents are commonly used in early resuscitation of patients with sepsis, but comparative data for prioritizing their delivery are limited. METHODS In an unblinded superiority trial conducted at 60 U.S. centers, we randomly assigned patients to either a restrictive fluid strategy (prioritizing vasopressors and lower intravenous fluid volumes) or a liberal fluid strategy (prioritizing higher volumes of intravenous fluids before vasopressor use) for a 24-hour period. Randomization occurred within 4 hours after a patient met the criteria for sepsis-induced hypotension refractory to initial treatment with 1 to 3 liters of intravenous fluid. We hypothesized that all-cause mortality before discharge home by day 90 (primary outcome) would be lower with a restrictive fluid strategy than with a liberal fluid strategy. Safety was also assessed. RESULTS A total of 1563 patients were enrolled, with 782 assigned to the restrictive fluid group and 781 to the liberal fluid group. Resuscitation therapies that were administered during the 24-hour protocol period differed between the two groups; less intravenous fluid was administered in the restrictive fluid group than in the liberal fluid group (difference of medians, -2134 ml; 95% confidence interval [CI], -2318 to -1949), whereas the restrictive fluid group had earlier, more prevalent, and longer duration of vasopressor use. Death from any cause before discharge home by day 90 occurred in 109 patients (14.0%) in the restrictive fluid group and in 116 patients (14.9%) in the liberal fluid group (estimated difference, -0.9 percentage points; 95% CI, -4.4 to 2.6; P = 0.61); 5 patients in the restrictive fluid group and 4 patients in the liberal fluid group had their data censored (lost to follow-up). The number of reported serious adverse events was similar in the two groups. CONCLUSIONS Among patients with sepsis-induced hypotension, the restrictive fluid strategy that was used in this trial did not result in significantly lower (or higher) mortality before discharge home by day 90 than the liberal fluid strategy. (Funded by the National Heart, Lung, and Blood Institute; CLOVERS ClinicalTrials.gov number, NCT03434028.).
Collapse
Affiliation(s)
- Nathan I Shapiro
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Ivor S Douglas
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Roy G Brower
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Samuel M Brown
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Matthew C Exline
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Adit A Ginde
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Michelle N Gong
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Colin K Grissom
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Douglas Hayden
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Catherine L Hough
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Weixing Huang
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Theodore J Iwashyna
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Alan E Jones
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Akram Khan
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Poying Lai
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Kathleen D Liu
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Chadwick D Miller
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Katherine Oldmixon
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Pauline K Park
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Todd W Rice
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Nancy Ringwood
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Matthew W Semler
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Jay S Steingrub
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Daniel Talmor
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - B Taylor Thompson
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Donald M Yealy
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| | - Wesley H Self
- From the Department of Emergency Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School (N.I.S.), the Biostatistics Center (D.H., W.H., P.L.) and the Department of Medicine (K.O., N.R., B.T.T.), Massachusetts General Hospital, and the Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center (D.T.), Boston, and the Department of Medicine, Baystate Medical Center, Springfield (J.S.S.) - all in Massachusetts; the Department of Medicine, Denver Health Medical Center, Denver (I.S.D.), and the Department of Emergency Medicine, University of Colorado School of Medicine, Aurora (A.A.G.) - both in Colorado; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (R.G.B., T.J.I.); the Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, and the Department of Medicine, University of Utah, Salt Lake City - both in Utah (S.M.B., C.K.G.); the Ohio State University Wexner Medical Center, Columbus (M.C.E.); the Department of Medicine, Montefiore Medical Center, Bronx, NY (M.N.G.); the Department of Medicine, Oregon Health and Science University, Portland (C.L.H., A.K.); the Department of Emergency Medicine, University of Mississippi Medical Center, Jackson (A.E.J.); the Department of Medicine, University of California, San Francisco, Medical Center, San Francisco (K.D.L.); the Department of Emergency Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.D.M.); the Department of Surgery, University of Michigan Medical School, Ann Arbor (P.K.P.); the Departments of Medicine (T.W.R., M.W.S.) and Emergency Medicine (W.H.S.), Vanderbilt University Medical Center, Nashville; and the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh (D.M.Y.)
| |
Collapse
|
46
|
Tenforde MW, Self WH, Zhu Y, Naioti EA, Gaglani M, Ginde AA, Jensen K, Talbot HK, Casey JD, Mohr NM, Zepeski A, McNeal T, Ghamande S, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Lohuis CT, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Botros MM, Lauring AS, Shapiro NI, Halasa N, Chappell JD, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Rhoads JP, Lindsell CJ, Hart KW, Turbyfill C, Olson S, Murray N, Adams K, Patel MM. Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clin Infect Dis 2023; 76:e460-e468. [PMID: 35580849 PMCID: PMC9129194 DOI: 10.1093/cid/ciac381] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 04/29/2022] [Accepted: 05/12/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were authorized in the United States in December 2020. Although vaccine effectiveness (VE) against mild infection declines markedly after several months, limited understanding exists on the long-term durability of protection against COVID-19-associated hospitalization. METHODS Case-control analysis of adults (≥18 years) hospitalized at 21 hospitals in 18 states 11 March-15 December 2021, including COVID-19 case patients and reverse transcriptase-polymerase chain reaction-negative controls. We included adults who were unvaccinated or vaccinated with 2 doses of a mRNA vaccine before the date of illness onset. VE over time was assessed using logistic regression comparing odds of vaccination in cases versus controls, adjusting for confounders. Models included dichotomous time (<180 vs ≥180 days since dose 2) and continuous time modeled using restricted cubic splines. RESULTS A total of 10 078 patients were included, 4906 cases (23% vaccinated) and 5172 controls (62% vaccinated). Median age was 60 years (interquartile range, 46-70), 56% were non-Hispanic White, and 81% had ≥1 medical condition. Among immunocompetent adults, VE <180 days was 90% (95% confidence interval [CI], 88-91) versus 82% (95% CI, 79-85) at ≥180 days (P < .001). VE declined for Pfizer-BioNTech (88% to 79%, P < .001) and Moderna (93% to 87%, P < .001) products, for younger adults (18-64 years) (91% to 87%, P = .005), and for adults ≥65 years of age (87% to 78%, P < .001). In models using restricted cubic splines, similar changes were observed. CONCLUSIONS In a period largely predating Omicron variant circulation, effectiveness of 2 mRNA doses against COVID-19-associated hospitalization was largely sustained through 9 months.
Collapse
Affiliation(s)
| | - Wesley H Self
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Yuwei Zhu
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | - Manjusha Gaglani
- Baylor Scott & White Health, Temple, Texas, USA.,Texas A&M University College of Medicine, Temple, Texas, USA
| | - Adit A Ginde
- University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Kelly Jensen
- University of Colorado School of Medicine, Aurora, Colorado, USA
| | - H Keipp Talbot
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | | | | | - Tresa McNeal
- Baylor Scott & White Health, Temple, Texas, USA.,Texas A&M University College of Medicine, Temple, Texas, USA
| | - Shekhar Ghamande
- Baylor Scott & White Health, Temple, Texas, USA.,Texas A&M University College of Medicine, Temple, Texas, USA
| | - Kevin W Gibbs
- Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA
| | - D Clark Files
- Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA
| | | | - Arber Shehu
- Johns Hopkins Hospital, Baltimore, Maryland, USA
| | | | | | - Michelle N Gong
- Montefiore Healthcare Center, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Amira Mohamed
- Montefiore Healthcare Center, Albert Einstein College of Medicine, Bronx, New York, USA
| | | | | | | | - Ithan D Peltan
- Intermountain Medical Center and University of Utah, Salt Lake City, Utah, USA
| | - Samuel M Brown
- Intermountain Medical Center and University of Utah, Salt Lake City, Utah, USA
| | - Emily T Martin
- University of Michigan School of Public Health, Ann Arbor, Michigan, USA
| | - Arnold S Monto
- University of Michigan School of Public Health, Ann Arbor, Michigan, USA
| | - Akram Khan
- Oregon Health & Science University Hospital, Portland, Oregon, USA
| | | | | | | | | | | | - Nida Qadir
- Ronald Reagan-UCLA Medical Center, Los Angeles, California, USA
| | - Steven Y Chang
- Ronald Reagan-UCLA Medical Center, Los Angeles, California, USA
| | | | | | | | | | - Matthew C Exline
- Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Mena M Botros
- Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Adam S Lauring
- University of Michigan School of Medicine, Ann Arbor, Michigan, USA
| | - Nathan I Shapiro
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Natasha Halasa
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | | | - Todd W Rice
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Ian D Jones
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | | | - Kelsey N Womack
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | | | - Kimberly W Hart
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | | | - Nancy Murray
- CDC COVID-19 Response Team, Atlanta, Georgia, USA
| | | | | | | |
Collapse
|
47
|
Bennett CL, Espinola JA, Ginde AA, Camargo CA. Attrition from emergency medicine clinical practice in the United States, 2020. Acad Emerg Med 2023; 30:139-143. [PMID: 36482871 DOI: 10.1111/acem.14640] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 11/22/2022] [Accepted: 12/07/2022] [Indexed: 12/13/2022]
Affiliation(s)
- Christopher L Bennett
- Department of Emergency Medicine, Stanford University School of Medicine, Palo Alto, California, USA
| | - Janice A Espinola
- Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Carlos A Camargo
- Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
48
|
McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, Jayaweera D, Sulkowski M, Gentile N, Bramante C, Singh U, Dolor RJ, Ruiz-Unger J, Wilson S, DeLong A, Remaly A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Thicklin F, Hanna G, Ginde AA, Castro M, McTigue K, Shenkman E, Hernandez AF. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 2023; 329:296-305. [PMID: 36633838 PMCID: PMC9857647 DOI: 10.1001/jama.2022.24100] [Citation(s) in RCA: 27] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 12/13/2022] [Indexed: 01/13/2023]
Abstract
Importance The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear. Objective To evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily) for 10 days compared with placebo for the treatment of mild to moderate COVID-19 in the US. Design, Setting, and Participants The ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) platform randomized clinical trial was designed to test repurposed medications in outpatients with mild to moderate COVID-19. A total of 1288 participants aged 30 years or older with test-confirmed SARS-CoV-2 infection and experiencing 2 or more symptoms of acute COVID-19 for 7 days or less were enrolled between August 6, 2021, and May 27, 2022, at 91 sites in the US. Interventions Participants were randomized to receive 50 mg of fluvoxamine twice daily for 10 days or placebo. Main Outcomes and Measures The primary outcome was time to sustained recovery (defined as the third day of 3 consecutive days without symptoms). There were 7 secondary outcomes, including a composite outcome of hospitalization, urgent care visit, emergency department visit, or death through day 28. Results Among 1331 participants who were randomized (median age, 47 years [IQR, 38-57 years]; 57% were women; and 67% reported receiving ≥2 doses of a SARS-CoV-2 vaccine), 1288 completed the trial (674 in the fluvoxamine group and 614 in the placebo group). The median time to sustained recovery was 12 days (IQR, 11-14 days) in the fluvoxamine group and 13 days (IQR, 12-13 days) in the placebo group (hazard ratio [HR], 0.96 [95% credible interval, 0.86-1.06], posterior P = .21 for the probability of benefit [determined by an HR >1]). For the composite outcome, 26 participants (3.9%) in the fluvoxamine group were hospitalized, had an urgent care visit, had an emergency department visit, or died compared with 23 participants (3.8%) in the placebo group (HR, 1.1 [95% credible interval, 0.5-1.8], posterior P = .35 for the probability of benefit [determined by an HR <1]). One participant in the fluvoxamine group and 2 participants in the placebo group were hospitalized; no deaths occurred in either group. Adverse events were uncommon in both groups. Conclusions and Relevance Among outpatients with mild to moderate COVID-19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04885530.
Collapse
Affiliation(s)
| | - Susanna Naggie
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
- Department of Medicine, School of Medicine, Duke University, Durham, North Carolina
| | - David R. Boulware
- Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis
| | | | - Thomas G. Stewart
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
- Now with School of Data Science, University of Virginia, Charlottesville
| | - G. Michael Felker
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
- Department of Medicine, School of Medicine, Duke University, Durham, North Carolina
| | - Dushyantha Jayaweera
- Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida
| | - Mark Sulkowski
- Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland
| | - Nina Gentile
- Department of Emergency Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania
| | - Carolyn Bramante
- Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis
| | - Upinder Singh
- Departments of Internal Medicine and Microbiology and Immunology, School of Medicine, Stanford University, Stanford, California
| | - Rowena J. Dolor
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
- Department of Medicine, School of Medicine, Duke University, Durham, North Carolina
| | | | - Sybil Wilson
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
| | - Allison DeLong
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
| | - April Remaly
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
| | - Rhonda Wilder
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
| | - Sean Collins
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Sarah E. Dunsmore
- National Center for Advancing Translational Sciences, Bethesda, Maryland
| | - Stacey J. Adam
- Foundation for the National Institutes of Health, Bethesda, Maryland
| | | | - George Hanna
- Biomedical Advanced Research and Development Authority, Washington, DC
| | - Adit A. Ginde
- Department of Emergency Medicine, University of Colorado, Denver
| | - Mario Castro
- Division of Pulmonary, Critical Care, and Sleep Medicine, School of Medicine, University of Missouri, Kansas City, Kansas
| | - Kathleen McTigue
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Elizabeth Shenkman
- Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville
| | - Adrian F. Hernandez
- Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
- Department of Medicine, School of Medicine, Duke University, Durham, North Carolina
| |
Collapse
|
49
|
Prekker ME, Driver BE, Trent SA, Resnick-Ault D, Seitz K, Russell DW, Gandotra S, Gaillard JP, Gibbs KW, Latimer A, Whitson MR, Ghamande S, Vonderhaar DJ, Walco JP, Hansen SJ, Douglas IS, Barnes CR, Krishnamoorthy V, Bastman JJ, Lloyd BD, Robison SW, Palakshappa JA, Mitchell S, Page DB, White HD, Espinera A, Hughes C, Joffe AM, Herbert JT, Schauer SG, Long BJ, Imhoff B, Wang L, Rhoads JP, Womack KN, Janz D, Self WH, Rice TW, Ginde AA, Casey JD, Semler MW. DirEct versus VIdeo LaryngosCopE (DEVICE): protocol and statistical analysis plan for a randomised clinical trial in critically ill adults undergoing emergency tracheal intubation. BMJ Open 2023; 13:e068978. [PMID: 36639210 PMCID: PMC9843219 DOI: 10.1136/bmjopen-2022-068978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
INTRODUCTION Among critically ill patients undergoing orotracheal intubation in the emergency department (ED) or intensive care unit (ICU), failure to visualise the vocal cords and intubate the trachea on the first attempt is associated with an increased risk of complications. Two types of laryngoscopes are commonly available: direct laryngoscopes and video laryngoscopes. For critically ill adults undergoing emergency tracheal intubation, it remains uncertain whether the use of a video laryngoscope increases the incidence of successful intubation on the first attempt compared with the use of a direct laryngoscope. METHODS AND ANALYSIS The DirEct versus VIdeo LaryngosCopE (DEVICE) trial is a prospective, multicentre, non-blinded, randomised trial being conducted in 7 EDs and 10 ICUs in the USA. The trial plans to enrol up to 2000 critically ill adults undergoing orotracheal intubation with a laryngoscope. Eligible patients are randomised 1:1 to the use of a video laryngoscope or a direct laryngoscope for the first intubation attempt. The primary outcome is successful intubation on the first attempt. The secondary outcome is the incidence of severe complications between induction and 2 min after intubation, defined as the occurrence of one or more of the following: severe hypoxaemia (lowest oxygen saturation <80%); severe hypotension (systolic blood pressure <65 mm Hg or new or increased vasopressor administration); cardiac arrest or death. Enrolment began on 19 March 2022 and is expected to be completed in 2023. ETHICS AND DISSEMINATION The trial protocol was approved with waiver of informed consent by the single institutional review board at Vanderbilt University Medical Center and the Human Research Protection Office of the Department of Defense. The results will be presented at scientific conferences and submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER ClinicalTrials.gov Registry (NCT05239195).
Collapse
Affiliation(s)
- Matthew E Prekker
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
| | - Brian E Driver
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
| | - Stacy A Trent
- Department of Emergency Medicine, Denver Health Medical Center, Denver, Colorado, USA
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Daniel Resnick-Ault
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Kevin Seitz
- Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Derek W Russell
- Pulmonary Section, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Sheetal Gandotra
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - John P Gaillard
- Department of Emergency Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, USA
- Department of Anesthesiology, Section on Critical Care, Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, USA
| | - Kevin W Gibbs
- Department of Medicine, Section of Pulmonary, Critical Care, Allergy and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Andrew Latimer
- Department of Emergency Medicine, University of Washington Harborview Medical Center, Seattle, Washington, USA
| | - Micah R Whitson
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Shekhar Ghamande
- Department of Medicine, Division of Pulmonary Disease and Critical Care Medicine, Baylor Scott & White Medical Center, Temple, Texas, USA
| | - Derek J Vonderhaar
- Department of Pulmonary and Critical Care Medicine, Ochsner Health, New Orleans, Louisiana, USA
| | - Jeremy P Walco
- Department of Anesthesiology, Division of Anesthesia Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Sydney J Hansen
- Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA
| | - Ivor S Douglas
- Division of Pulmonary and Critical Care Medicine, Denver Health Medical Center, Denver, Colorado, USA
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Christopher R Barnes
- Department of Anesthesiology and Critical Care Medicine, University of Washington Harborview Medical Center, Seattle, Washington, USA
| | - Vijay Krishnamoorthy
- Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina, USA
| | - Jill J Bastman
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Bradley Daniel Lloyd
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Sarah W Robison
- Pulmonary Section, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Jessica A Palakshappa
- Department of Medicine, Section of Pulmonary, Critical Care, Allergy and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Steven Mitchell
- Department of Emergency Medicine, University of Washington Harborview Medical Center, Seattle, Washington, USA
| | - David B Page
- Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Heath D White
- Department of Medicine, Division of Pulmonary Disease and Critical Care Medicine, Baylor Scott & White Medical Center, Temple, Texas, USA
| | - Alyssa Espinera
- Department of Pulmonary and Critical Care Medicine, Ochsner Health, New Orleans, Louisiana, USA
| | - Christopher Hughes
- Department of Anesthesiology, Division of Anesthesia Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Aaron M Joffe
- Department of Anesthesiology and Critical Care Medicine, University of Washington Harborview Medical Center, Seattle, Washington, USA
| | - J Taylor Herbert
- Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina, USA
| | - Steven G Schauer
- US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - Brit J Long
- 59th Medical Wing, Joint Base San Antonio-Lackland, Texas, USA
| | - Brant Imhoff
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Li Wang
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Jillian P Rhoads
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Kelsey N Womack
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - David Janz
- Department of Medicine, Section of Pulmonary/Critical Care Medicine and Allergy/Immunology, University Medical Center New Orleans, New Orleans, Louisiana, USA
| | - Wesley H Self
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Todd W Rice
- Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Jonathan D Casey
- Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Matthew W Semler
- Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| |
Collapse
|
50
|
Douin DJ, Dylla L, Anderson EL, Rice JD, Jackson CL, Bebarta VS, Neumann RT, Schauer SG, Ginde AA. Hyperoxia is associated with a greater risk for mortality in critically ill traumatic brain injury patients than in critically ill trauma patients without brain injury. Sci Prog 2023; 106:368504231160416. [PMID: 36879502 PMCID: PMC10450323 DOI: 10.1177/00368504231160416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023]
Abstract
OBJECTIVE The role of hyperoxia in patients with traumatic brain injury (TBI) remains controversial. The objective of this study was to determine the association between hyperoxia and mortality in critically ill TBI patients compared to critically ill trauma patients without TBI. DESIGN Secondary analysis of a multicenter retrospective cohort study. SETTING Three regional trauma centers in Colorado, USA, between October 1, 2015, and June 30, 2018. PATIENTS We included 3464 critically injured adults who were admitted to an intensive care unit (ICU) within 24 h of arrival and qualified for inclusion into the state trauma registry. We analyzed all available SpO2 values during the first seven ICU days. The primary outcome was in-hospital mortality. Secondary outcomes included the proportion of time spent in hyperoxia (defined as SpO2 > 96%) and ventilator-free days. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS In-hospital mortality occurred in 163 patients (10.7%) in the TBI group and 101 patients (5.2%) in the non-TBI group. After adjusting for ICU length of stay, TBI patients spent a significantly greater amount of time in hyperoxia versus non-TBI patients (p = 0.024). TBI status significantly modified the effect of hyperoxia on mortality. At each specific SpO2 level, the risk of mortality increases with increasing FiO2 for both patients with and without TBI. This trend was more pronounced at lower FiO2 and higher SpO2 values, where a greater number of patient observations were obtained. Among patients who required invasive mechanical ventilation, TBI patients required significantly more days of ventilation to day 28 than non-TBI patients. CONCLUSIONS Critically ill trauma patients with a TBI spend a greater proportion of time in hyperoxia compared to those without a TBI. TBI status significantly modified the effect of hyperoxia on mortality. Prospective clinical trials are needed to better assess a possible causal relationship.
Collapse
Affiliation(s)
- David J Douin
- Department of Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA
| | - Layne Dylla
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Erin L Anderson
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - John D Rice
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA
| | - Conner L Jackson
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA
| | - Vikhyat S Bebarta
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA
- Center for COMBAT Research, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Robert T Neumann
- Department of Neurological Surgery, University of Colorado School of Medicine, Aurora, CO, USA
| | - Steven G Schauer
- US Air Force 59th Medical Wing, Office of the Chief Scientist, JBSA, Lackland, TX, USA
- US Army Institute of Surgical Research, JBSA Fort Sam Houston, TX, USA
| | - Adit A Ginde
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
- Center for COMBAT Research, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| |
Collapse
|